Review

Human Induced Pluripotent Stem Cell-Derived Vascular Cells: Recent Progress and Future Directions

Jee Eun Oh 1,2, Cholomi Jung 1,3 and Young-sup Yoon 1,2,4,*

1 Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul 03722, Korea; jeeunoh@yuhs.ac (J.E.O.); cjung90@yuhs.ac (C.J.)
2 Research and Development Center, KarisBio Inc., 50-1 Yonsei-ro, Avison Biomedical Research Center Room 525, Seodaemun-gu, Seoul 03722, Korea
3 Department of Internal Medicine, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul 03722, Korea
4 Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA 30322, USA
*

Abstract: Human induced pluripotent stem cells (hiPSCs) hold great promise for cardiovascular regeneration following ischemic injury. Considerable effort has been made toward the development and optimization of methods to differentiate hiPSCs into vascular cells, such as endothelial and smooth muscle cells (ECs and SMCs). In particular, hiPSC-derived ECs have shown robust potential for promoting neovascularization in animal models of cardiovascular diseases, potentially achieving significant and sustained therapeutic benefits. However, the use of hiPSC-derived SMCs that possess high therapeutic relevance is a relatively new area of investigation, still in the earlier investigational stages. In this review, we first discuss different methodologies to derive vascular cells from hiPSCs with a particular emphasis on the role of key developmental signals. Furthermore, we propose a standardized framework for assessing and defining the EC and SMC identity that might be suitable for inducing tissue repair and regeneration. We then highlight the regenerative effects of hiPSC-derived vascular cells on animal models of myocardial infarction and hindlimb ischemia. Finally, we address several obstacles that need to be overcome to fully implement the use of hiPSC-derived vascular cells for clinical application.

Keywords: human induced pluripotent stem cell; endothelial cell; smooth muscle cell; stem cell; cardiovascular disease; regenerative medicine

1. Introduction

Ischemic cardiovascular disease is the leading cause of global morbidity and mortality [1–3]. In a significant population of patients, existing surgical and interventional treatments in combination with medical therapy are not effective because the anatomical complexity, aging, multiple procedures, and comorbidities may leave patients with no option, or at least poor options, for revascularization [4–8]. Such clinical limitations justify the search for an alternative therapeutic option that may beneficially influence the outcomes of these no-option patients.

Cell-based therapy offers an unprecedented opportunity to treat ischemic cardiovascular disease that requires revascularization. Its mechanism is mainly governed by the concept of neovascularization, which means formation of new blood vessels [9,10]. Neovascularization occurs through three distinct processes: vasculogenesis, angiogenesis, and arteriogenesis (reviewed in detail by Carmeliet [11], Jain [12], and Simons [13]). Briefly, vasculogenesis refers to the de novo formation of the primitive vascular plexus from stem or progenitor cells during embryogenesis [14], whereas angiogenesis is a process through which new capillaries are formed not only from pre-existing vessels but also by proliferation, sprouting, and migration of endothelial cells (ECs) [15,16]. Lastly, arteriogenesis is the
extensive growth of relatively larger vessels, such as arterioles and arteries [17,18]. In arteriogenesis, smooth muscle cells (SMCs) are recruited to cover the EC layer, thereby resulting in vessel maturation and stabilization [19–22]. While ECs are the most basic building block of blood vessels and capable of forming capillary-like vessels, SMCs are unequivocally necessary for the development of a mature and durable vasculature [11,13,23–25]. Thus, cell-based therapy using vascular cells, such as ECs and SMCs, is an approach to induce therapeutic neovascularization, which not only rebuilds a vasculature but also restores blood perfusion and cardiac or vascular function.

Earlier studies used a myriad of adult stem or progenitor cells to induce neovascularization. While effective in animal models of myocardial infarction [26–29] and hindlimb ischemia [30–32], clinical trials have produced controversial results [33–36], with modest effects at best. Mechanistically, adult stem or progenitor cells exert therapeutic effects, mainly through paracrine effects [37–39]. Accordingly, the use of human embryonic stem cells (hESCs) was proposed as a new therapeutic option for cardiovascular regeneration. Human ESCs, which are the inner cell mass of the blastocyst, are pluripotent and can differentiate into any cell type of the ectodermal, mesodermal, and endodermal lineage [40,41]. Furthermore, hESCs can maintain pluripotency and proliferative capacity [42]. Differentiation of hESCs into ECs and SMCs have been demonstrated [43–47]. While a plethora of studies have revealed the experimental promise of hESC-derived vascular cells in animal models of myocardial infarction [48,49] and hindlimb ischemia [50–52], their clinical application is significantly hampered by immunogenicity due to allogeneic use and ethical concerns about obtaining human embryos.

Yamanaka and colleagues reported generation of human induced pluripotent stem cells (hiPSCs) in 2006 [53]. This new cell type has opened a new era of stem cell biology, cell-based therapy, and regenerative medicine. Originally, human iPSCs (hiPSCs) were generated from adult human dermal fibroblasts with retroviral vectors containing four transcription factors, POU5F1 (OCT4), SOX2, KLF4, and MYC [54]. Thereafter, various cell sources such blood [55–58] and urine [59,60], other inducing factors such as LIN28, NANOG, and microRNAs [61,62] and other delivery vectors including plasmids [63,64] and modified mRNAs [65,66] have been developed, allowing clinical application [67]. Human iPSCs are similar to hESCs in molecular and genetic features, morphology, pluripotency and unlimited proliferation potential. Of note, they have additional advantages over hESCs in that they are free of ethical controversy and autologous cell generation is possible. With these characteristics, hiPSCs have emerged as strong candidates for cell-based therapy. Owing to their multilineage differentiation potential, they have shown promising results in their differentiation into ECs and SMCs, which are crucial sources for vascular regeneration.

In this review, we discuss the methods for differentiating hiPSCs into ECs and SMCs, collectively called vascular cells. We then review criteria to define the identity of hiPSC-derived ECs and SMCs. We further explore the therapeutic potential of hiPSC-derived vascular cells in animal models of cardiovascular diseases. Lastly, we describe challenges for clinical application of these two types of cells (Figure 1).
Figure 1. Proposed scheme for clinical application of hiPSC-derived vascular cells to treat patients with ischemic cardiovascular diseases. (a) Human iPSCs can be generated from somatic cells, such as skin fibroblasts and blood cells. Human iPSCs can differentiate into either ECs or SMCs via intermediates. The resulting vascular cells can be used for cell-based therapy to induce neovascularization. Solid arrows indicate verified and validated steps. Dashed arrows indicate speculative steps yet to be demonstrated. (b) Transplanted hiPSC-derived ECs incorporate into vessels, which are covered by hiPSC-derived SMCs, to form neovascularization in ischemic regions.

2. Human Induced Pluripotent Stem Cell-Derived Endothelial Cells

In regenerative medicine, hiPSC technology has brought a new era for inducing neovascularization. Shortly after the first discovery of murine iPSCs and human iPSCs [53,54,68], studies showed successful differentiation of hiPSCs into ECs in 2009 [69]. Taura et al. evaluated the feasibility and compatibility of EC differentiation from four different hiPSC lines compared to three hESC lines. After this first successful EC generation, much effort was made to define and optimize hiPSC-EC differentiation processes. In this section, the advances in hiPSC-EC differentiation systems are reviewed, denoting EC features to postulate their functionality in neovascularization.

2.1. Differentiation of hiPSCs into ECs

Traditional differentiation methods of hiPSC-derived ECs include embryoid body (EB)-mediated and monolayer-directed approaches. EBs, aggregated masses of pluripotent stem cells in suspension culture, can spontaneously differentiate into ECs. However, due to the spontaneous process that leads three-germ layered EBs to differentiate into multiple lineage cells, the system holds two critical limitations: inconsistency and low yield.
Although endothelial differentiation of hESCs through EB-mediated methods was first achieved as early as 2002, the differentiation yield was only 2% [44]. Likewise, the first hiPSC-derived ECs by Taura et al. yielded less than 5% of the total population [69]. In 2011, Rufaihah et al. [70] were able to differentiate hiPSCs into ECs with better efficiency, ranging from 5 to 20%, via the EB-mediated method. Supplemented with EC-inducing factors BMP4 and VEGF in the culture media, hiPSC-ECs that were positive for PECAM1, CDH5, NOS3, and VWF were generated. As the 3D protocols are laborious and complex, involving dissociation of 3D aggregates and further expansion in 2D monolayered culture [71,72], simple 2D differentiation systems without EB formation were developed. The 2D monolayered system often comprises coculture techniques with other cell types or feeder-free methods. However, because it is imperative to exclude contamination from feeder cells used for attachment, such as mouse embryonic fibroblasts (MEFs), we only discuss here the protocols using coating matrices such as collagen, Matrigel, or Fibronectin [73,74]. Moreover, the 2D differentiation system is advantageous over the 3D system because homogeneous exposure of culture media permits more consistent EC derivation and much improved yields [75]. Studies have shown that hiPSC-derived ECs using a simple 2D differentiation system resulted in efficiency exceeding 80–98% [73,76,77]. Here, we focus on EC-directed 2D differentiation approaches, which are organized into distinct stages via sequential treatments of defined conditions for growth factors, cytokines, and small molecules (Figure 2).

**Figure 2.** Proposed strategies to derive endothelial cells from hiPSCs via mesodermal lineages. Combinations of growth factors, cytokines, small molecules, transcription factors and phenotypic markers that define mesodermal cells or ECs are listed. Dashed lines indicate that hiPSC-derived ECs can be further differentiated into arterial, venous, and lymphatic EC subtypes.

Adapted from mammalian embryo development, the first step for generating endothelial cells is to differentiate hPSCs into the mesodermal lineage [78–80]. In the embryo, the mesoderm layer gives rise to primordial vascular cells [14,81]. It was previously established that Wnt signaling is necessary for embryonic mesoderm induction, especially for early primitive streak formation and gastrulation, shown by studies of mice deficient in the Wnt3, Wnt coreceptors Lrp5 and Lrp6, and β-catenin [82–84]. Lindsley et al. then confirmed that canonical Wnt activity in vivo was conserved during the equivalent steps of ESC-derived mesoderm differentiation [85]. Upon inhibition of endogenous Wnt signaling, generation of Kdr+ mesodermal precursors and mature mesodermal lineages failed, and mesoderm-specific genes were not induced. In addition, a morphogen, BMP4, promotes
gastrulation and ventral mesoderm formation and is responsible for the dorsal-ventral axis alignment [86,87]. It was also noted that BMP4, as a member of the TGF-β superfamily, initiates Wnt signaling pathways and activates activin/nodal pathways to generate the primitive streak in mice [88,89]. In hESC cultures, BMP4 also triggered Wnt and nodal signaling to generate early embryonic germ layers [90,91]. It was also reported that GSK3β inhibition by CHIR99021 or CP21R7 in combination with BMP4 treatment allowed rapid commitment to mesodermal cell fate [76]. Synergistic effects may be provoked because activation of canonical Wnt/β-catenin signaling initiates molecular cascades that ultimately inhibit GSK3β [92]. FG2 is also used in mesodermal differentiation. In early Xenopus and zebrafish studies, it was demonstrated that FGF signaling also plays an important role in the formation and maintenance of axial and paraxial mesoderm [93–96]. Fletcher and Harland specified that FGF signaling did not affect axial mesoderm induction but maintenance, whereas it directly induced paraxial mesoderm formation [96]. PI3K catalytic activity, acting downstream of FGF2 signaling, is also required for mesoderm formation during early Xenopus development [97]. In mouse ESC studies, Yamaguchi et al. demonstrated that Fgf2 is involved in mesoderm patterning via FGF receptor type I [98]. However, in humans, the specific function of FGF2 in the commitment of mesodermal cells from hESCs to endothelial lineage is yet to be clarified [78]. Studies have demonstrated that FGF2 is required to maintain the undifferentiated state of hESCs, and its inhibition enhances BMP4-mediated differentiation towards the mesoderm [99–101]. While FGF2 and PI3K/Akt activity maintains self-renewal in hESCs, inhibition of PI3K/Akt signaling promotes the differentiation of mesoderm and endoderm [102]. Thus, the overall balance of canonical Wnt/β-catenin, activin/nodal, and BMP signaling needs to be carefully controlled for early lineage specification during hiPSC-EC differentiation [103].

In efforts to efficiently differentiate ECs from hiPSCs through mesodermal lineage, combinations of such essential factors have been applied. In 2014, Orlova et al. improved the 2D mesoderm differentiation protocol generating functional ECs [104]. With treatments of BMP4, VEGF165, CHIR99021 and activin A for 3 days before replacing with endothelial inducing medium, the KDR+CD34+ mesodermal population showed an activin A-dependent increase (about 13%) by day 10. In the same year, Lian et al. successfully generated TBXT+ mesodermal cells from hiPSCs treated with CHIR99021 alone [105]. This suggested the possibility of lowering differentiation costs by using a single chemical inhibitor. In 2015, Patsch et al. attempted to identify chemical GSK3β inhibitors that promote hiPSCs toward mesoderm transition [76]. CHIR99021 or CP21R7 were the most effective, and in combination with BMP4 for Wnt activation resulted in a significant upregulation of genes associated with mesoderm, TBXT, MIXL1, and EOMES, and accumulation of TBXT expression levels, which peaked at day three. Patsch et al. confirmed that these GSK3β inhibitors with BMP4 and VEGFA in differentiation medium enhanced the efficiency exceeding 80%. Soon after, Liu et al. [106] specified that the size of hiPSC colonies, seeding densities of the colonies on Matrigel-coated dishes, and addition of CHIR99021 are critical with regard to mesoderm differentiation. Consistent with these findings, Lee et al. [73] demonstrated that transcriptional expression of TBXT and KDR was highly induced in conditions using collagen-coated surface and CHIR99021 treatment for three days. Enhanced hiPSC-mesodermal transition, resulting in more than 51% KDR+ population at this stage, enables more improved efficiency in EC differentiation. More recently, in 2020 Wang et al. used a condition of 48 h CHIR99021 treatment to convert hiPSCs into mesodermal progenitor cells and observed transient activation of mesodermal transcription factors MIXL1 and TBXT [107].

Less commonly, studies have reported generation of hematopoietic/endothelial lineage progenitor cells from hiPSCs via CD34+ sorting. Supplemental BMP4 directed hESC differentiation towards both hematopoietic and endothelial cells [108,109]. Chadwick et al. [108] demonstrated that high levels of BMP4 enhanced hematopoietic stem cell survival, whereas Goldman et al. [109] reported that a short and high-dose boost of BMP4 in addition to VEGF accelerated CDH5+KDR+ endothelial commitment in vitro.
In 2009, Choi et al. [110] obtained hiPSC-derived CD34+ cells that can differentiate into both hematopoietic and endothelial lineages. According to Yang et al. [111], CD34+ cells exhibited a more adherent endothelial progenitor-like phenotype under endothelial culture conditions, exhibiting the robust mRNA expression of endothelial markers VWF, CDH5, and KDR. Prasain et al. [112] optimized concentrations of activin A, BMP4, FGF2, and VEGF, critical for the emergence of mesodermal cells and thus ECs, compared to previous EC differentiation protocols. They generated hiPSC-derived intermediate cells positive for PECAM1 and NRP1, which give rise to CB-ECFC-like cells displaying a stable endothelial phenotype and possessing a high proliferative capacity. Double EC markers, CD34+PECAM1+, CD34+CDH5+, or CD34+KDR+ were used to isolate endothelial lineage cells. Moreover, Li et al. [113] used partially-induced hPSCs that transiently expressed only Oct4 and Klf4 for endothelial differentiation. They gradually changed supplements in the culture medium, exchanging BMP4 with 8-Br-cAMP in addition to VEGF and FGF2, thereby creating ‘induced’ ECs (iEnd cells).

The second step for endothelial cell generation is to differentiate mesodermal lineage cells into ECs by various combinations of growth factors, cytokines, and small molecules. In addition to VEGF, the central factor of endothelial differentiation, hiPSC-derived ECs, are often generated by adding BMP4, FGF2, a TGF-β receptor I inhibitor (SB431542), a cAMP inducer (forskolin), and DLL4. VEGF acts as a key regulator of vasculogenesis and EC migration in angiogenesis [114]. VEGF signaling through VEGFR1 and VEGFR2 is transduced to mediate PI3K/Akt pathways. Mouse and zebrafish studies have shown that VEGF stimulates EC migration, merging into blood islands, and formation of the first primitive vascular plexus in the embryo [114]. In a hESC-derived EC study, VEGF plays an indispensable role for EC differentiation promoting expression of EC-specific proteins, although continuous treatment of VEGF was not able to enhance the rate of EC proliferation per se [115]. Genetic studies in mice revealed that BMP4 and FGF2 are not only critical for mesoderm formation but also play important roles in EC differentiation [78]. Mice deficient for BMP4 downstream effectors, such as Smad5 or Smad4, lacked an organized yolk sac vasculature or displayed severe cell proliferation defects [116,117]. Ribatti et al. demonstrated that FGF2 signaling is important for in vivo formation of extraembryonic blood vessels [118]. FGF2 plays an important role in controlling endothelial homeostasis by maintaining endothelial fate. By inhibition of TGF-β signaling cascade, FGF2 prevents endothelial-mesenchymal transition and sustains endothelial features [119,120]. DLL4 has been shown to enhance the efficacy of EC differentiation but inhibit hematopoietic-lineage differentiation. Liu et al. [121] reported for the first time that VEGF can induce NOTCH1 and its ligand DLL4 in human arterial ECs. Small molecules such as SB431542, an inhibitor of TGF-β receptor I and or forskolin, a cAMP inducer, in combinations with VEGF can also promote efficient EC conversions from hPSCs [75].

Aiming for efficient and clinically applicable differentiation of hiPSC-derived ECs, optimization of EC-promoting media with defined conditions has been attempted. Wang et al. [122] differentiated hiPSC-derived ECs in medium containing VEGF, BMP4, FGF2 in the first stage, and SB431542 (TGF-β inhibitor) and Y27632 (ROCK inhibitor) in the next stage. Their protocol resulted in 60% purity and, within only one week, they achieved ECs exhibiting strong expression of the EC markers, PECAM1 and VWF, able to form capillary-like networks, and mimicking inflammatory responses of primary ECs. To induce endothelial lineage cells, Lee et al. [73] cultured hiPSC-derived mesodermal lineage cells in medium containing VEGF, FGF2, EGF, DLL4 and heparin and sorted the differentiated cells at day 14 with CDH5 antibody. Addition of DLL4 increased the PECAM1+, CDH5+, VWF+ cell population confirming that DLL4 further promotes EC differentiation. In 2017, Ikuno et al. [123] established that cAMP synergistically enhances VEGF effects in hiPSC-derived EC induction by supplementing with activin A, BMP4, FGF2, 8-Br-cAMP, and VEGF in the EC induction medium. By sorting with CDH5 and/or PECAM1 antibodies at 9 days after differentiation, they acquired an EC population at more than 99% purity. To perform large-scale single cell RNA sequencing, Paik et al. [124] generated hiPSC-derived ECs via
mesodermal lineage differentiation. The cells were subjected to a commercial EC medium supplemented with BMP4, VEGF, and FGF2. They isolated CDH5+ cells on day 12 and further cultured in EGM2 medium supplemented with SB431542.

Recent studies have reported EC lineage differentiation from mesodermal cells via ETS variant 2 (ETV2) overexpression. It is well known that early induction of ETV2 expression is essential for embryonic vascular development. ETV2 is a member of the ETS family of transcription factors that is important for cell proliferation, differentiation, and migration [125]. These transcriptional regulators also play a critical role in EC development. The regulatory domains of many endothelial-specific genes contain ETS binding sites that include a core GGAA/T DNA sequence [126]. De Val et al. demonstrated that ETV2, in particular, regulates the differentiation of mesodermal progenitors toward hematopoietic and endothelial cell fate [127]. An enhanced level of expression of Etv2 promotes expression levels of endothelial-specific genes, suggesting it is necessary and sufficient for endothelial cell development in vivo. In 2020, Wang et al. generated ectopic expression of ETV2 by chemically modified mRNA (modRNA) for the mesoderm-to-endothelial differentiation stage [107]. Independent of exogenous VEGFA signaling, constant activation of synthetic ETV2 in mesodermal lineage cells generated sufficient numbers of ECs in a rapid and robust manner [107]. It was shown that the differentiation efficiency was higher than 90%. Rather than activating endogenous ETV2 expression by exogenous VEGF exposure, enhanced ETV2 expression level was achieved by introducing modRNA to mesodermal cells via electroporation or lipofection-mediated methods. Indeed, studies reported that increased expression of ETV2 in hiPSCs facilitates bypassing of the intermediate mesodermal stage to generate functional ECs [128–130], whereas most of the vascular differentiation approaches comprise sequential transitions. Interestingly, one recent study has revealed that transient expression of transcription factor ETV2 is sufficient to directly reprogram somatic cells into ECs [131].

Endothelial specification for arterial, venous or lymphatic EC fates can be further induced in vitro, whereas in the developing embryo the primitive vascular plexus is specialized into arterial, venous or lymphatic-fated angioblasts [132,133]. In 2013, Rufaihah et al. [134] revealed that an hiPSC-derived EC population, purified for PECAM1, exhibited EC subtype heterogeneity, displaying arterial, venous and lymphatic lineage markers. Recently, Arora et al. [135] extensively reviewed heterogeneity within differentiated EC populations from PSCs and described phenotypic and functional differences between arterial and venous ECs. Moreover, through sequential EC maturation processes, arterial and venous-like ECs develop into functional blood vessels, such as arteries, veins and capillaries. In the late 1990s, Wang et al. [136] demonstrated that EFNB2 and its receptor EPHB4, mark arterial and venous ECs, respectively. Genetically arterial and venous ECs are distinguished by elevated expression of EFNB2, NRP1, NOTCH1, DLL4, and Jagged for arterial, and EPHB4, NRP2, and NR2F2 for venous ECs [135,136]. In 2014, Corada et al. [137] also reviewed signaling pathways, particularly Wnt, Sox, and Notch pathways, and transcription factors implicated in endothelial subtype specification. As a critical inducing agent, VEGF is not only required for EC proliferation by binding to KDR or VEGFR1, but also for specification of EC fates by binding to VEGFR2; with high and low concentrations leading to arterial and venous ECs, respectively [138–140]. Rosa et al. [141] succeeded in inducing hiPSC-derived arterial and venous-like ECs with chemically defined conditions via two-step differentiation protocols. Initially, hiPSCs were differentiated into endothelial precursor cells, marked as PECAM1+/KDR+/CDH5med/EPHB2−/NR2F2−. These cells were then directed into arterial or venous-like ECs by either high or low concentration of VEGF. Rosa et al. confirmed that hiPSC-derived arterial-like ECs produced more NO and elongated upon shear stress compared to hiPSC-derived venous-like ECs, consistent with a previous study conducted by Zhang et al. [142]. Further analysis is required to determine whether arterial or venous ECs are more effective for neovascularization.
2.2. Criteria to Define EC Identity

To validate the EC characteristics of hiPSC-derived ECs via various approaches, their molecular, cellular, and functional features must be carefully analyzed. Even though the differentiated cells can be purified with antibodies against EC-specific surface markers [69,73,76], it is essential to demonstrate key characteristics of ECs in hiPSC-derived ECs in a comprehensive manner. In this section, we summarize essential criteria for defining hiPSC-derived ECs (Table 1).

### Table 1. Criteria to define the EC identity.

| Characteristics                          | Methods                  | Expected Features                                      |
|------------------------------------------|--------------------------|--------------------------------------------------------|
| Cell morphology                          | Bright-field/phase-contrast microscopy | Cobblestone-like shape with a single nucleus           |
| Increased expression of EC-specific markers | RT-PCR, Western blot, Flow cytometry, Immunocytochemistry | KDR, CDH5, VWF, PECAM1, TEK, and NOS3                  |
| In silico analysis                       | Microarray, RNA-sequencing, Single-cell RNA-sequencing, Single-cell ATAC-sequencing | Upregulation of EC-specific genes Enriched GO terms related to ECs Comparison with human primary ECs |
| In vitro functionality                   | Immunocytochemistry, ELISA | NO production Uptake of acetylated LDL                  |
|                                          | RT-PCR, Western blot, ELISA | Elevated expression of angiogenic factors, including VEGFA, ANGPT1, IGF1, and FGF2 |
|                                          | Cell migration            | Increased overall motility                             |
|                                          | Tube formation            | Tube-like structure formation                          |

Conventionally, differentiated ECs are assessed for their morphology, EC-specific marker expression, and functionality in vitro. Microscopic observation is the primary technique to distinguish differentiated ECs from hiPSCs. The typical ‘cobblestone’ monolayer pattern of ECs should be seen at stationary density [143]. Molecular features of EC must be then addressed. Elevated expression of KDR, CDH5, VWF, PECAM1, TEK, and NOS3 at mRNA and protein levels are expected in hiPSC-derived ECs. Although human ECs are heterogenous among organs and tissues, the genetic profiles acquired by Marcu et al. [144] confirmed that general EC markers, such as PECAM1, CDH5, and VWF are commonly expressed across organs including heart, lung, liver, and kidney. Protein expression levels and localization of such markers in hiPSC-derived ECs need to be demonstrated by Western blotting and immunostaining methods. Differentiated hiPSC-ECs should display CDH5 and KDR on the cell surface, CDH5 and PECAM1 at cell junctions, VWF and ANGPT2 in Weibel-Palade bodies (endothelial restricted organelles), and NOS3 at perinuclear regions and the plasma membrane [145]. Nevertheless, expression levels of these markers may be altered depending on the maturity of hiPSC-derived ECs. For example, KDR expression is sustained in young endothelium [131], whereas it had been often used as a marker for mesodermal lineage progenitors [69,73,104]. Mature hiPSC-derived ECs may display different protein profiles compared to immature ones. For instance, White et al. demonstrated that hiPSC-derived endothelial progenitor cells expressing only KDR were further differentiated into more mature ECs expressing CDH5 and PECAM1 [146]. Patel et al. revealed that PECAM1 is a marker for more mature, but not young, ECs [147]. Likewise, Adams et al. revealed that a KDR+ PECAM1+ double positive population of hiPSC-derived ECs lacked CDH5 expression while a subpopulation of PECAM1+ cells may also express the hematopoietic marker CD45 [145]. Thus, we suggest that combinations of EC markers
be used to support endothelial differentiation from hiPSCs. In addition, functional abilities of hiPSC-derived ECs, such as NO production and AcLDL uptake, should be assessed. NO production is certainly one of the most crucial characteristics of ECs. Constant release of NO, encoded by endothelial-specific NOS3, controls vessel tone [148,149] and stimulates cell migration and angiogenesis [114]. Thus, quantification of NOS3 expression at both the mRNA and protein levels should be documented from hiPSC-derived ECs. Indeed, NO release could be easily measured by fluorescent bioimaging techniques [150–152] that quantify nitrate-to-nitrite conversion. Also, Dil-labeled AcLDL is frequently used as an endothelial marker. Angiogenic properties of hiPSC-derived ECs can be included, as hiPSC-ECs are enriched with proangiogenic factors. Expression of proangiogenic factors such as VEGF, IGF1, ANGPT1 and FGF2 can be measured at the molecular level by RT-PCR or ELISA [50]. Cell migration assay and tube-like network formation assay are essential, because in the native environment during angiogenesis and sprouting, ECs are stimulated to migrate, forming new capillaries. In a cellular migration assay, cell migration toward a cell-free gap in a monolayered culture is quantified in comparison with other cell types [153]. Tube formation ability of hiPSC-derived ECs is often analyzed on a Matrigel 3D matrix [154]. The number of branching points and branch lengths are measured. In silico analyses of hiPSC-EC transcriptome via RNA sequencing can also be performed. Paik et al. utilized a droplet-based method to determine single-cell RNA sequencing of hiPSC-derived ECs [124]. Based on sequencing data analysis, their hiPSC-EC differentiation protocol produced a large population of iPSC-ECs but also other cell types of mesodermal lineages. They discovered that the generated hiPSC-ECs population were predominantly arterial-like ECs, with low numbers of venous and lymphatic ECs.

3. Human Induced Pluripotent Stem Cell-Derived Smooth Muscle Cells

A number of methods have been developed to differentiate hiPSCs into vascular SMCs. The use of EB, which mimics early embryonic development in mammals, provided the opportunity to directly differentiate into SMCs [155–159]; however, owing to the line-to-line variability in efficiency and labor-intensive nature of EB-based protocols, the monolayer-based protocols have been favored. Accordingly, in this section, we review recent progress in monolayer-based differentiation systems of hiPSCs towards SMCs.

3.1. Differentiation of hiPSCs into Lineage-Specific SMC Intermediates

Before considering any method for differentiation of hiPSCs into SMCs, it is essential to note that vascular SMCs arise from distinct developmental origins (reviewed in detail by Majesky [160], and also by Sinha et al. [161]). For example, a fraction of vascular SMCs are neuroectodermally derived neural crest cells, while most originate from the mesodermal lineages, including the lateral plate and paraxial mesoderm [162–164]. Accordingly, this principle was extended to generate hiPSC-derived lineage-specific SMC intermediates before differentiating further into vascular SMCs (Figure 3). In the same vein as the developmental process from which hiPSC-derived ECs emerge, several strategies to derive lineage-specific SMC intermediates from hiPSCs also depend on key factors involved in embryonic vascular development.

Studies have shown that hiPSCs could be differentiated into vascular SMCs through the neural crest lineage. In general, different combinations of the FGF [165–167], BMP [168–170], Wnt [171,172], TGF-β [173,174], RA [175,176], and/or activin/nodal [177,178] signals were utilized and optimized to differentiate into a neural crest lineage endowed with SMC potential [179]. Wang et al. [180] introduced a protocol to allow derivation of neural crest stem cells from hiPSCs before differentiating into SMCs. Their method was sufficient to give rise to NES+/B3GAT1+/NGFR+/TFAP2A+ cells by using a publicly available neural supplement with FGF2 and EGF. However, one caveat in this study was that their neural rosette-based method was time-consuming, taking at least 22 days, and obtained a relatively low yield. In 2012 and 2014, Cheung et al. [181–183] provided a detailed characterization of neural crest cells derived from hiPSCs. The former adopted their
previously published protocol [184] using a chemically defined medium supplemented with FGF2 and activin/nodal inhibitor SB431542, while the latter was a combination of FGF2, SB431542, and a BMP inhibitor, noggin [185], resulting in a substantial amount of GBX2+/OLIG3+/SOX1+ neuroectodermal cells. In addition, PAX3 and NES were observed in these cells by immunocytochemistry. The differentiated cells were then isolated by FACS with antibodies against NGFR and B3GAT1. Enriched gene expression of PAX3, NGFR, B3GAT1, and TEAP2A was detected in the sorted cells. It is noteworthy that the concept of systemically deriving three lineage-specific SMC intermediates from a single hiPSC in vitro was first reported by Cheung et al. [181], as studies from a number of different groups have only featured the generation of a single lineage-specific SMC intermediate from hiPSCs, mainly of the mesodermal lineage. Based on the results from previous studies [181,186], Halaidych et al. [187] found that a combination of FGF2 and SB431542, with a small molecular Wnt activator, CHIR99021, was the most efficient in induction of the neural crest lineage. FACS analysis on day 12 of differentiation showed that approximately 40–50% of cells were positive for NGFR and B3GAT but negative for TRA-1-60 and SOX2. This cell population was further enriched by mechanical removal of undifferentiated colonies, and expressed the increased gene expression of TEAP2A, SOX9 and 10, and PAX3. Their protocol was highly reproducible in the three different hiPSC lines. These studies show that careful control over the inductive and inhibitory signals should be exercised for specification of the neural crest.

**Figure 3.** Proposed strategies to derive lineage-specific SMC intermediates from hiPSCs. Derivation of lineage-specific SMC intermediates from hiPSCs recapitulates the defining events of early embryonic development and cell lineage specification in vertebrate embryos. Combinations of growth factors, cytokines and phenotypic markers that define each cell type are listed.

As vascular SMCs mostly originate from the mesoderm during development, many protocols for generating vascular SMCs from hiPSCs include a mesodermal step. Developmentally, canonical Wnt signaling is indispensable for the mesoderm commitment [85,188]. For one, mice carrying a null mutation in Wnt signaling display defects in mesoderm formation [82,189,190]. Moreover, Wnt signals act in concert with activin/nodal and BMP signaling to specify mesodermal cell fate [103,191]. Each morphogen can elicit mesodermal responses with a tightly controlled concentration gradient, whereas the members of the FGF family do so over relatively broad ranges [192]. Such spatiotemporal presenta-
tion inevitably translates into distinct mesoderm subtypes [193]. For example, Cheung et al. [181] demonstrated the feasibility of deriving two lineage-specific SMC mesodermal intermediates from hiPSCs: lateral plate and paraxial mesoderm. Human iPSCs were initially differentiated into early mesoderm using a combination of FGF2, BMP4, and a PI3K inhibitor in which a primitive streak [194,195] and early mesoderm marker [196], TBXT, emerged and peaked at 36 h. For further specification to the lateral plate mesoderm, only FGF2 and BMP4 were added to upregulate gene expression of lateral plate mesoderm markers, including MESP1, KDR, NKX2-5, and ISL1. In contrast, a combination of only FGF2 and a PI3K inhibitor increased the gene expression of paraxial mesoderm markers, including TBX6, MEOX1, TCF15, and PAX1. Concomitant protein expression of lateral plate (KDR, ISL1, NKX2-5) and paraxial mesoderm markers (TCF15 and TBX6) was observed under these two conditions. Their method gave similar results in subsequent studies from Iyer et al. [197], and Granata et al. [198]. To differentiate lateral plate mesodermal cells into the epicardial lineage, Iyer et al. revealed that modulation of WNT3A, BMP4, and RA signals is responsible. A strategy developed by Patsch et al. was to identify selective GSK3β inhibitors that promote canonical Wnt signaling to direct the differentiation of hiPSCs into mesodermal cells [76]. It was shown that CHIR99021 and a commercially available compound, CP21R7, were the most efficient in induction of the mesodermal lineage, and concerted treatment with BMP4 enhanced its differentiation efficiency. Treatment of hiPSCs with CHIR99021 and BMP4 led to upregulation of TBXT, MIXL, and EOMES; conversely, these TBXT+ cells showed a significant reduction in the expression of POU5F1. Similar results were obtained using CP21R7 and BMP4. Using the same recipe as in a publicly available B27 supplement, Yang et al. [199] directed hiPSCs towards the mesodermal lineage. However, in vitro characterization of hiPSC-derived mesodermal cells was not investigated in this study. Kwong et al. [200] provided a novel approach to differentiate hiPSCs into the mesodermal lineage, which was adapted from a previously published protocol from Prasain et al. [112]. Human iPSCs were first cultured in a serum-free medium supplemented with activin A, FGF2, BMP4, and VEGF165 for a day, and then the medium was replaced with a commercially available hematopoietic stem cell expansion medium containing FGF2, BMP4, and VEGF165 for three days. At day four, Kwong et al. identified a population of putative mesodermal cells with robust KDR expression, which was also enriched for a lateral plate mesoderm marker, FOXF1. Synergistic combinations of key developmental signals can program hiPSCs to differentiate into the mesodermal lineage.

While there is a plethora of cell culture methodologies to differentiate hiPSCs to the mesodermal lineage, many have attempted to obtain hiPSC-derived vascular SMCs from other SMC intermediates. Intriguingly, groups of investigators first differentiated hiPSCs into CD34+ (with PECAM1+) progenitor cells [105,201–203]. For example, Lian et al. [105] and Bao et al. [203] showed that a combination of ascorbic acid and CHIR99021 was sufficient to induce a population of CD34+/PECAM1+ progenitor cells. Under alternate differentiation conditions, sorted cells could give rise to both ECs and SMCs. In 2012, Bajpai et al. [204] provided a stepwise process that began with an epithelial-to-mesenchymal transition from hiPSCs to highly proliferative and multipotent mesenchymal stem cells (MSCs), not mesodermal cells, in a commercially available human vascular SMC basal medium containing SM differentiation supplement with 5% FBS, FGF2, EGF, heparin, and insulin. Human iPSC-derived MSCs acquired the characteristics of MSCs, expressing high levels of NT5E, THY1, ITGA2, CD44, and ENG. The resulting cells displayed differentiation potential to obtain an osteogenic, adipogenic, and/or chondrogenic phenotype, before specifying towards a SMC lineage. Innovatively, Kumar et al. [205] proposed that mesodermal pericytes and SMCs derived from hiPSCs originate from an endothelial and mesenchymal cell precursor, the mesenchymoangioblast. Initially employed in an hESC differentiation system in 2010 [206], Kumar et al. differentiated hiPSCs into a mesodermal cell population with BMP4, activin A, and FGF2, using the cocktail developed by Uenishi et al. [207]. The APLNR+/PDGFRα+ mesodermal cells were then molded into FGF2-dependent compact spheroid colonies that exhibited both mesenchymal and endothe-
lial potentials. These colonies further morphed into mesenchymoangioblasts expressing NGFR+/ENG+/PDGFRβ+/MCAM+/NT5E−. Mesenchymoangioblasts reminiscent of lateral plate mesoderm-derived embryonic mesenchyme later gave rise to either pericytes or SMCs. Collectively, these strategies for inducing differentiation of hiPSCs to nonspecific and lineage-specific SMC intermediates offer valuable insights into the developmental pathways that are crucial for vascular SMC biology.

3.2. Differentiation of hiPSCs into Specialized SMC Phenotypes

Unlike either skeletal or cardiac muscle cells, SMCs retain a remarkable phenotypic plasticity, reversibly shifting along a continuum from a quiescent, contractile phenotype to a proliferative, synthetic phenotype (reviewed in detail by Owens et al. [208]) (Figure 4). Thus, a similar but distinct differentiation method must be applied to derive each phenotype from hiPSCs.

![Figure 4. Proposed strategies to derive synthetic and contractile SMCs from hiPSCs.](image)

Taura et al. [69] were the first to generate mural cells from the four hiPSC cell lines. Although differentiation efficiency was low, Taura et al. used a protocol that was previously established for hESCs [43] to sort for a population of KDR+/CDH5−/TRA-1-60− cells. Sorted cells were further differentiated into mural cells using only PDGF-BB. These PDGF-BB-treated cells expressed ACTA2+/CNN1+, reminiscent of vascular SMCs. Similarly, Patsch et al. [76] treated mesodermal cells with PDGF-BB and activin A in a mixture of two commercially available supplements, N2 and B27 (N2B27), for two days. The resulting cells expressed PDGFRβ+/CDH5− and were cultured in N2B27 medium supplemented with PDGF-BB for another five to seven days to obtain hiPSC-derived synthetic SMCs. Alternatively, to promote a contractile SMC phenotype, the treated cells were cultured in N2B27 medium supplemented with activin A and heparin. The resulting cells also expressed ACTA2, TAGLN, and MYH11b, and exhibited a transcriptional signature and metabolic profile similar to human pulmonary and aortic vascular SMCs. Differentiated SMCs were functional, as these cells were capable of responding to vasoconstrictive stimuli as shown by calcium imaging and a collagen gel contraction assay, demonstrating their contractility. Lastly, the differentiated SMCs deposited extracellular fibronectin, confirming their functionality [209]. However, Patsch et al. routinely used both human ESC and iPSC lines, which were denoted as hiPSCs; thus, there was no indication as to which hiPSC line was
employed. Lastly, Karamariti et al. [210] cultured partial-iPSCs with PDGF-BB for six days, as previously developed by Xiao et al. [211]. The differentiated partial-iPSCs expressed a repertoire of contractile SMC-specific markers (ACTA2, TAGLN, CNN1, MYH11, SMTN, MYOCD, and SRF) at the mRNA level, and ACTA2, TAGLN, and CNN1 at the protein level. Immunocytochemistry for TAGLN and CNN1 demonstrated a SMC-like morphology in the differentiated partial-iPSCs. Stimulation of partial-iPSC-derived SMCs with KCl caused a strong contraction, which was similar to human SMCs. Interestingly, treatment with a member of DKK3 demonstrated an upregulation of SMC-specific marker expression in the DKK3-treated cells at both the mRNA and protein levels. Groups of investigators demonstrated the importance of PDGF-β/PDGFR-β signaling in mural cell specification, as signaling is required for vascular integrity during blood vessel development [212–214].

TGF-β signaling is implicated in the development of the contractile SMC phenotype [215–217]. Consequently, Wang et al. [180] further derived SMCs of neural crest origin using 5% FBS and TGF-β1 only. After two weeks of culture, these cells showed the assembly of ACTA2, TAGLN, and CNN1 into stress fibers, but with diffuse cytoplasmic staining of MYH11. In addition, Bajpai et al. [204] tested different combinations and found that a combination of TGF-β1 and heparin induced relatively higher gene expression of ACTA2, TAGLN, CALD1, CNN1, and MYH11 in hiPSC-derived SMCs. Similarly, immunocytochemistry showed a filamentous organization of ACTA2, CNN1, and MYH11 in these cells. One defining property of mature SMCs is to produce force in response to vasoactive agonists. Bajpai et al. thus fabricated small-diameter cylindrical tissue constructs by embedding hiPSC-derived SMCs in fibrin hydrogels. After two weeks of culture in medium containing TGF-β1, insulin, and ascorbic acid, the tissue constructs, which were distributed uniformly and circumferentially with the hiPSC-SMCs, exhibited robust force generation in response to vasoactive agonists, and superior mechanical strength. Lastly, Kumar et al. [205] used TGF-β1 and sphingosylphosphorylcholine together to produce hiPSC-derived SMCs and provided detailed morphological and functional characteristics of immature and mature hiPSC-derived SMCs. Human iPSC-derived SMCs became much larger and acquired the typical rhomboid morphology of synthetic SMCs. Although the cells showed increased expression of ACTA2 and CNN1, a population of highly proliferative and expandable cells were designated as immature SMCs. Based on a finding that a MAPK1 cascade plays a critical role in the regulation of protein synthesis in SMCs [218], Kumar et al. treated immature hiPSC-SMCs with the MAP2K7 inhibitor PD0325901, whereby they acquired a more elongated morphology and expressed a mature SMC marker, MYH11. There was a substantial increase in the expression of other SMC markers, ACTA2, DES, and CNN1, in mature hiPSC-SMCs. In addition, gene expression profiling revealed a unique molecular signature for transition from immature to mature hiPSC-derived SMCs. A significant upregulation of typical SMC genes, including ACTA2, TAGLN, CNN1, MYH11, MYOCD, MYLK, LMOD1, and SYNPO2, and genes enriched in the KEGG categories, including focal adhesion and vascular SMC contraction, was consistent with the maturation of SMCs. To determine the contractile properties of hiPSC-derived SMCs, Kumar et al. performed time-lapse studies of individual cells treated with carbachol. Mature hiPSC-SMCs responded to carbachol treatment much more strongly and contracted in a tonic fashion. Similarly, these mature cells exhibited the strongest basal contractile tone in the gel lattice assay, and to a much lesser degree in immature hiPSC-derived SMCs. Finally, a Matrigel plug assay showed the capacity of hiPSC-derived SMCs to support vasculature formation in vivo. The results suggested that TGF-β signaling might be required to induce differentiation of mature and contractile SMCs.

As both PDGF-BB and TGF-β1 play crucial roles in induction of a vascular SMC phenotype, Cheung et al. tested the two to differentiate three different lineage-specific SMC intermediates from hiPSCs into contractile SMCs [181–183]. Treatment with PDGF-BB and TGF-β1 promoted the elevated gene expression of early-intermediate (ACTA2, TAGLN, and CNN1) and late (MYH11 and SMTN) SMC markers at day 12. Flow cytometric analysis correlated with the gene expression profile, generating more than 80% ACTA2+/MYH11+
and TAGLN+ /MYH11+ cells. Immunocytochemistry demonstrated extensive staining for CNN1 and TAGLN in the derived SMCs. Western blot also revealed an increase in the protein expression of mature SMC markers MYH11 and SMTN in the derived SMCs. A microarray analysis was conducted to characterize the derived SMCs, showing upregulation of vascular SMC genes. Cheung et al. [181] further assessed their contractile potential by first detecting a change in intracellular calcium flux and then by measuring a change in surface area of cell size in response to carbachol treatment. As a result, hiPSC-derived SMCs possess contractile function. To determine whether these cells could contribute to vessel formation in vivo, a Matrigel plug of mixed human umbilical cord vein endothelial cells (HUVEC) and hiPSC-derived SMCs was subcutaneously implanted into immunodeficient mice for two weeks. Human iPSC-derived SMCs stained for SMTN were recruited to peri-endothelial regions. A complete in vitro characterization of hiPSC-derived SMCs was provided by Cheung et al. [181,183]. Halaidych et al. [187] differentiated neural crest cells derived from hiPSCs into vascular SMCs using previously described protocols [181,198,219–221], with some modifications. There were five modified protocols involved with different combinations of TGF-β3, PDGF-BB, and FBS. Gene expression of contractile SMC markers, including ACTA2, TAGLN, CNN1, and MYH11, was similar in hiPSC-derived SMCs from the five differentiation protocols. Likewise, a contractile phenotype was confirmed by immunocytochemistry for ACTA2, TAGLN, and CNN1. Halaidych et al. further demonstrated subpopulations of hiPSC-derived SMCs with varying intracellular calcium release and reuptake, but mostly with strong contractions in response to a vasoconstritor. Kwong et al. [200] also used a combination of TGF-β1 and PDGF-BB to directly differentiate into hiPSC-derived SMCs. Kwong et al. sought to engineer putative SMCs from hiPSCs by targeting an eGFP reporter to the endogenous human ACTA2 locus. At day 30, about 36% of ACTA2eGFP+ cells were present, and the sorted cells expressed the characteristics of vascular SMCs in which ACTA2, TAGLN, and MYH11 were increased at the mRNA level. A transcriptomic profile of the ACTA2eGFP+ and ACTA2eGFP- cells verified that the ACTA2eGFP+ cell population was suggestive of an immature and/or synthetic SMC phenotype. Lastly, Yang et al. [199] presented two protocols for differentiating into either a synthetic or contractile SMC phenotype of the mesodermal lineage. To differentiate into a synthetic SMC phenotype, the mesodermal cells were treated with different combinations of (1) VEGFA and FGF2 in a publicly available B27 supplement minus insulin for four days; (2) VEGFA and FGF2 in a B27 supplement for two days, and (3) PDGF-BB and TGF-β1 in a B27 supplement for four days. To differentiate into a contractile SMC phenotype, the mesodermal cells were treated with combination (1) for four days, and with combination (3) for six days. The differentiated cells were then enriched for SMCs in a medium containing lactate for four to six days. While the purified cells from each differentiation protocol showed more than 90% of ACTA2+ cells, hiPSC-derived contractile SMCs showed the relatively higher gene expression of MYH11, CNN1, and TAGLN than did synthetic SMCs. However, hiPSC-derived synthetic SMCs were more likely to express COL1A1, GJA1, and VIM. Immunocytochemistry demonstrated much higher protein expression of CNN1 in hiPSC-derived contractile SMCs. Differences in their functionality were detected. Human iPSC-derived synthetic SMCs were highly migratory and proliferative, whereas contractile SMCs were more contracted in response to carbachol treatment. The size of fibrinogen gels suspended in each cell type was measured after three days. Gels containing hiPSC-derived contractile SMCs contracted to approximately 27% of their original size, compared to 46% for gels containing synthetic SMCs. Yang et al. utilized a metabolic selection to purify the hiPSC-derived contractile SMCs. Two major factors, PDGF-BB and TGF, are frequently used to specify towards SMC phenotypes. More faithful recapitulation of the developmental pathways that undergo SMC specifications may represent an efficient route to improve the differentiation yield and purity.
3.3. Criteria to Define the Contractile SMC Identity

In all methods for differentiation of hiPSCs, it is imperative to define the key characteristics of the desired cell type, such as ECs and cardiomyocytes. However, this task has proven particularly daunting for hiPSC-derived SMCs, as their heterogeneity in origin contributes to the varying functions and expression of SMC-specific markers [222–225]. Phenotypic switching of vascular SMCs, which constantly fluctuate between a proliferative, migratory, ECM-producing, immature, and synthetic phenotype and a quiescent, mature, and contractile phenotype, further adds to the SMC heterogeneity (reviewed in detail by Owens et al. [208]). As such, a clear understanding of what constitutes mature and contractile SMCs is desperately needed. Differentiation efficiency can, therefore, be reported by means of (1) flow cytometric analysis for contractile SMC-specific markers, (2) quantitative analysis using SMC-specific fluorescent reporter hiPSC lines, and/or (3) quantitative analysis of intracellular calcium release and contraction in hiPSC-derived SMCs. In this section, we highlight the characteristics that must be present to consider a cell a mature and contractile SMC (Table 2).

| Characteristics | Methods | Expected Features |
|-----------------|---------|-------------------|
| Cell morphology | Bright-field/phase-contrast microscopy | Spindle-shaped with a single nucleus |
|                 | Transmission electron microscopy     | Enhanced filamentous patterns and dense bodies |
| Increased expression of contractile SMC-specific markers | RT-PCR | ACTA2, TAGLN, CALD1, DES, CNN1, MYH11, and SMTN |
|                 | Western blot | | |
|                 | Flow cytometry | | |
|                 | Immunocytochemistry | | |
| (Optional) Detection of contractile SMC fate determining transcription factors | RT-PCR | SRF, MYOCD, MRTFA and B, CRIP1 and 2, and PITX2 |
|                 | Western blot | | |
|                 | Flow cytometry | | |
|                 | Immunocytochemistry | | |
| Transcriptome analysis | Microarray RNA-sequencing | Upregulation of contractile SMC-specific genes |
|                 | Single-cell RNA-sequencing | Enriched GO terms related to contractile SMCs |
| In vitro functionality | Contraction | Responsive to vasoactive agents |
|                 | Intracellular calcium release | | |
|                 | Force generation | | |

Examination of the cell morphology is a major indicator to define cell identity. Nonetheless, morphological differences in SMCs are often observed because of their heterogeneity and phenotypic switching. Typically, contractile SMCs are elongated and spindle-shaped, whereas synthetic SMCs are epithelioid or rhomboid-shaped [226]. Electron microscopy more accurately reflects the ultrastructural features of the hiPSC-SMCs. The arrangement of cytoplasmic dense bodies and their relationship to the filaments should be detected. As a general consensus holds that there is no single marker exclusively definitive for a mature and contractile SMC phenotype, hiPSC-derived SMCs should express a collection of contractile SMC-specific markers such as ACTA2, TAGLN, CALD1, DES, CNN1, MYH11, and SMTN at the mRNA and protein levels [208]. To date, the two markers that best define a mature and contractile SMC phenotype are MYH11 and SMTN. Immunocytochemistry for these proteins should reveal proper structural organization of thick and thin filaments.
Downregulation of pluripotency markers, such as TRA-1-60, SSEA-3, POU5F1, and SOX2, should be apparent in hiPSC-derived SMCs. Although not necessarily required, expression of SMC fate-determining transcription factors that govern the transition to a contractile SMC phenotype can be determined. They are SRF [227], MYOCD [228–230], MRTFA and B [231], CRIP1 and 2 [232], and PITX2 [233]. Furthermore, a global analysis of gene expression using microarray, RNA-sequencing, or even single-cell RNA-sequencing, can be performed to further determine whether hiPSC-derived SMCs bear a strong resemblance to human contractile SMCs. The most reliable feature that a bona fide contractile SMC can show is its contractibility. The two commonly used functional assays, which are based on live-cell imaging, are (1) quantitative analysis of intracellular calcium release, and (2) contraction in response to vasoactive agonists. For the former, live human iPSC-derived SMCs are initially preloaded with a calcium-sensitive fluorescent dye and treated with vasoconstrictors to measure the oscillation of intracellular calcium concentrations by fluorescence imaging. For the latter, live human iPSC-derived SMCs are simply stimulated with a vasoconstrictor, and a series of images are acquired to calculate changes in the surface area of individual cells. The functionality of hiPSC-derived SMCs should then be compared with that of human SMCs. Recently, Halaidych et al. [187] provided open-source software for automated and unbiased analysis of intracellular calcium release kinetics and contractions by tracking individual cells. Thus, functional assessment of hiPSC-derived SMCs is of particular importance to distinguish between a contractile and noncontractile SMC phenotype. Taken together, contractile SMCs derived from hiPSCs should manifest all of the expected characteristics and functions, expressing contractile SMC markers and contracting in response to vasoconstrictors.

4. Therapeutic Applications Using hiPSC-Derived Vascular Cells

In this section, we discuss the feasibility and efficacy of hiPSC-derived vascular cells in animal models of experimental myocardial infarction and hindlimb ischemia before these cells can be applied to clinical application (Table 3).

Rufaihah et al. [70] were the first to demonstrate the therapeutic potential of hiPSC-derived ECs in a mouse model of hindlimb ischemia. When delivered into ischemic hindlimbs, hiPSC-derived ECs improved blood perfusion as seen by laser Doppler perfusion imaging and increased blood capillary density. Rufaihah et al. showed that injected hiPSC-derived ECs, mostly located in close proximity with only a few cells incorporated into the microvasculature, survived only up to 14 days. In concordance with these results, Clayton et al. [234] reported that perfusion recovery and capillary density were enhanced in the hiPSC-derived EC-injected ischemic tissues up to 14 days. Some transplanted hiPSC-derived ECs that were transduced with a GFP reporter construct were colocalized with PECAM1+ capillaries, indicating incorporation of these cells into the microvasculature. Although the two studies showed the regenerative effects of hiPSC-derived ECs in a mouse model of hindlimb ischemia, Rufaihah et al. [70] and Clayton et al. [234] only looked at their short-term in vivo behavior. Similarly, Lai et al. [235] intramuscularly injected hiPSC-derived ECs into three sites of ischemia hindlimbs and performed serial laser Doppler perfusion imaging up to 28 days. Lai et al. revealed that implantation of hiPSC-derived ECs enhanced blood flow and capillary density, which attenuated severe hindlimb ischemia in mice. However, their study was limited since they did not monitor the fate of transplanted hiPSC-derived ECs but only the similarities shared by generated ECs from different sources, including hiPSC-EC, hESC-EC, hBM-EC and HUVEC. Thus, the precise contribution of the hiPSC-derived ECs to neovascularization remained unknown. As these investigators showed low cell viability and survival after 28 days in a mouse model of hindlimb ischemia, the use of biomaterials such as hydrogels [236,237] and a nanomatrix gel [73] during cell delivery was applied in subsequent studies. Mulyasasmita et al. [236] developed a codelivery system of hiPSC-derived ECs with VEGF in a MICTH-PEG hydrogel, which not only provided significant protection from cell damage but also improved tissue regeneration and reduced inflammation in a mouse model of hindlimb ischemia. Foster et al. [237] also
showed enhanced hiPSC-EC retention in vivo and improved neovascularization of the ischemic limbs following the delivery of hiPSC-derived ECs in a hybrid hydrogel called SHIELD. Biomaterial-encapsulated hiPSC-derived EC delivery appeared to improve the survival of implanted hiPSC-derived ECs, which allowed these transplanted cells to exhibit their regenerative effects in vivo. Lee et al. [73] were the only researchers to demonstrate that hiPSC-derived ECs encapsulated in peptide amphiphile-nanomatrix gel survived for more than ten months in the ischemic environment in vivo and improved therapeutic neovascularization. At the histological level, Lee et al. showed that a large population of these hiPSC-derived ECs, which possessed regenerative capacity, were incorporated into the host vessels, and contributed to new vessel formation. Additionally, iPSC-derived ECs have been evaluated in animal models of experimental myocardial infarction. Gu et al. [238] successfully generated porcine iPSC-derived ECs and showed their therapeutic potential to treat myocardial infarction in a porcine model. Collectively, the therapeutic potential of hiPSC-derived ECs in vivo is well-established.

| Cell Type            | Number of Cells/Head | Delivery Method       | Species (Sex)               | Animal Model          | Reference |
|----------------------|----------------------|-----------------------|-----------------------------|------------------------|-----------|
| hiPSC-derived EC     | 5 × 10⁵               | Intramuscular injection | NOD/SCID mouse (male)       | Hindlimb ischemia     | [70]      |
| hiPSC-derived EC     | 1 × 10⁶               | Intramuscular injection | NOD/SCID mouse (male)       | Hindlimb ischemia     | [234]     |
| hiPSC-derived EC     | 3 × 10⁶               | Intramuscular injection | SCID mouse (male)           | Hindlimb ischemia     | [235]     |
| hiPSC-derived EC     | 5 × 10⁵               | Intramuscular injection | NOD/SCID mouse (male)       | Hindlimb ischemia     | [236]     |
| hiPSC-derived EC     | 1 × 10⁶               | Intramuscular injection | NOD/SCID mouse (male)       | Hindlimb ischemia     | [237]     |
| hiPSC-derived pericyte | 2 × 10⁶             | Intramuscular injection | Athymic nude Foxn1nu mouse (male) | Hindlimb ischemia     | [73]      |
| hiPSC-derived SMC    | 1 × 10⁶               | Intramuscular injection | Athymic nude Foxn1nu mouse (male) | Myocardial infarction | [238] *   |
| hiPSC-derived SMC    | 2 × 10⁶               | Intramuscular injection | CD-1 nude mouse (male)      | Hindlimb ischemia     | [239]     |

* Differentiated ECs were derived from porcine iPSCs. NOD/SCID: nonobese diabetic/severe combined immunodeficiency; SCID: severe combined immunodeficiency; CD-1: immunodeficient developed from the transfer of the nude gene from Crl:NU-Foxn1nu at Charles River Laboratories, Wilmington, MA, USA.

Similarly, direct contribution of transplanted hiPSC-derived SMCs to neovascularization was assessed in animal models of ischemic cardiovascular diseases. Dar et al. [239] used a murine model of hindlimb ischemia to determine whether hiPSC-derived pericytes contribute to neovascularization. In addition to an accelerated recovery of perfusion, the vessel density was significantly higher in the hiPSC-derived pericyte-injected ischemic limbs. Histological analysis showed that fluorescent-labeled differentiated cells not only retained their perivascular features in vivo but also incorporated into host blood vessels, indicating their putative therapeutic role in regenerative medicine. Recently, Gao et al. [240] determined the therapeutic potential of hiPSC-derived SMCs in a murine model of hindlimb ischemia. Human iPSC-derived SMCs were intramuscularly injected at the sites of ischemia and ameliorated ischemia. Laser Doppler perfusion images demonstrated improved blood flow in the differentiated cell-injected mice, and histological findings correlated with functional outcomes, which had an increase in the fibrosis area and capillary
density, and number of arterioles. Expression of VEGFA was significantly elevated with transplantation of hiPSC-derived SMCs, promoting VEGF-mediated angiogenesis. The results indicate that hiPSC-derived SMCs are a promising source to treat cardiovascular diseases. While efforts were recently made to evaluate the regenerative effects of hiPSC-derived SMCs on animal models of ischemic cardiovascular diseases, more studies are certainly needed.

While this is not the major focus of this review, hiPSC-derived vascular cells have also been utilized as a cell source for vascular tissue engineering. Specifically, tissue-engineered vascular grafts (TEVGs) using hiPSC-derived SMCs have been developed to serve as an innovative option to replace diseased blood vessels [158,200,210,219,241]. To date, TEVGs using hiPSC-derived SMCs have demonstrated significant mechanical strength and implantability [242]. Further studies should be directed to engineer a vascularized and permeable yet durable tissue graft, potentially transferring towards clinical applications.

5. Challenges and Future Directions

While the therapeutic potential of hiPSC-derived vascular cells has been demonstrated in animal models of myocardial infarction and hindlimb ischemia, several challenges must be overcome prior to their clinical translation. One major challenge using hiPSCs for cell therapy is the heterogeneity (genetic variability) of hiPSC lines and their derivatives. According to a review by Liang and Zhang [243], there are considerable genetic and epigenetic variations between the hiPSC lines and even between different passages of the same line. Such variations potentially influence their inherent pluripotency and differentiation capacity. This risk can be eliminated to a certain degree by using non-integrating vectors. For example, Hu et al. [244] established an integration-free hiPSC line from patient peripheral blood mononuclear cells through episomal vector nucleofection of the Yamanaka factors, which they successfully differentiated into functional SMCs. However, to minimize the associated risk, extensive genomic and epigenomic profiling should be conducted to exclude any lines with accumulated mutations.

Another concern is clinical compatibility of hiPSC-derived vascular cells. This embodies the following features: (1) establishment of fully defined and xenogeneic-free conditions to maintain the hiPSC lines and to differentiate into vascular cells; (2) optimization of protocols, which results in a highly reproducible differentiation efficiency and preferentially reduces cost and culture duration; (3) extensive in vitro characterization of hiPSC-derived vascular cells; and (4) isolation and/or purification of targeted vascular cells. First, hiPSCs must be differentiated in conditions that are not only fully defined but also free of xenogeneic components, as the use of animal serum and/or animal-derived feeder cells precludes clinical applications. One recent study by Luo et al. [245] established an efficient method for deriving functional hiPSC-derived SMCs under xenogeneic-free conditions. In addition, clinically compatible differentiation systems should be optimized to produce target cells with a highly reproducible efficiency. Then, in vitro characterization of the hiPSC lines and their derivatives should be provided to ensure their cell identity. Moreover, for a successful clinical translation of cell-based therapy using hiPSCs, a reliable and efficient method to purify or sort only target cells while preserving cell viability is a critical step. Although antibodies against surface makers, such as CDH5 [69,73,76], and PECAM1 [104,246], have been used for purification of hiPSC-derived ECs, there are as yet no applicable antibodies to target only hiPSC-derived SMCs. Yang et al. [199] used a metabolic selection to purify hiPSC-derived contractile SMCs; however, changes in metabolism may influence stemness and cell fate specification [247,248]. Thus, a novel method must be developed to obtain a homogenous population of hiPSC-derived contractile SMCs. Collectively, meticulous planning is extremely important to produce clinically compatible systems to derive functional vascular cells from various hiPSC lines.

Although many of the limitations indicated above have been addressed for hiPSC-derived ECs such that they are now considered an emerging therapeutic agent for human ischemic cardiovascular diseases, clinical conditions and requirements must be fulfilled.
before any clinical trials are initiated [249]. They include the safety of hiPSC-derived ECs as a drug, and risk assessments [250]. Prior to using hiPSC-ECs in human investigational applications, stringent preclinical analyses are required, following the government’s Chemistry, Manufacturing and Controls (CMC) recommendations for cell-based therapy. Importantly, absence of residual undifferentiated iPSCs from hiPSC-derived ECs must be ensured, because teratoma formation from residual undifferentiated iPSCs has been one of the major concerns in stem cell-based therapy [251]. Side-by-side experiments by Gutierrez-Aranda et al. showed that tumorigenesis with hiPSCs occurs even faster and more aggressively than with hESCs, regardless of the site of injection [252]. In association with the safety concerns, the identity and purity of hiPSC-EC products must also be assessed. HLA typing [253] and biodistribution of implanted cells [254] should be addressed. In addition, reproducibility of the biologics should be established without considerable batch-to-batch variation in large-scale cell production. Moreover, in vitro and in vivo functionality tests should be conducted to ensure the quality control of hiPSC-derived ECs. Cell viability is important. Lastly, it is vital to optimize the procedure to obtain a sufficient number of functional hiPSC-derived ECs, considering industrial-scale production, in the most efficient and cost-effective ways.

Over the years, poor cell survival and engraftment have been hurdles to overcome in many cell types; however, recent studies have shown improved survival of hiPSC-derived ECs with or without biomaterials. Many studies have used various biomaterials to encapsulate hiPSC-derived ECs and have shown improved cell survival [73,236,237,255]. Interestingly, Lee et al. [73] demonstrated the relatively longer (approximately ten months) survival of injected hiPSC-derived ECs in ischemic hindlimbs even without biomaterials, and showed improved survival and neovascularization when hiPSC-ECs were encapsulated in a nanomatrix gel. While it is clear that biomaterials enhance cell viability and survival in the ischemic region and sustain therapeutic performance of transplanted hiPSC-derived vascular cells, it is imperative to evaluate the clinical compatibility and safety of biomaterials for cell transplantation.

Conversely, the use of hiPSC-derived SMCs to enhance recovery from ischemia and promote tissue regeneration has recently been under investigation [239,240]. More studies are needed to ensure their therapeutic effects. Therefore, we address the following considerations for hiPSC-derived SMCs. There is, of course, a major question regarding the ideal SMC phenotype for stimulating neovascularization to re-build a functional blood vessel. In a series of early studies between 1999 and 2006, many evaluated the effects of transplanted SMCs on animal models of cardiovascular diseases. Five studies by Li et al. [256], Sakai et al. [257], Fujii et al. [258], Liu et al. [259], and Nakamura et al. [260] all showed that transplanted rat SMCs prevented cardiac dilation and improved heart function after a myocardial infarction. Meanwhile, Yoo et al. [261] and Yoo et al. [262] isolated SMCs from the ductus deferens of hamsters and determined that SMC transplantation improved left ventricular function and limited ventricular dilatation in a hamster model of dilated cardiomyopathy. As exemplified in these animal studies, in vitro characterization of cultured SMCs was assessed by staining for either ACTA2 or MYH11. Therefore, the findings provide an important clue that a contractile SMC phenotype might be more suitable, but the ideal SMC phenotype for clinical use must be addressed before hiPSC-derived SMCs become a clinical reality. Secondly, as previously mentioned, SMCs undergo remarkable phenotypic switching that allows rapid adaptation to external cues [224]. While maintaining either a synthetic or contractile SMC phenotype in cultured hiPSC-derived SMCs is relatively manageable, little is known about the fate of transplanted hiPSC-derived SMCs in vivo. Ultimately, long-term follow-up studies in animals should be conducted to determine the behavior and safety of transplanted hiPSC-derived SMCs.

**Author Contributions:** Conceptualization, J.E.O., C.J. and Y.-s.Y.; writing—original draft preparation, J.E.O. and C.J.; writing—review and editing, Y.-s.Y.; supervision, Y.-s.Y.; visualization, J.E.O. and C.J.; funding acquisition, Y.-s.Y. All authors have read and agreed to the published version of the manuscript.
**Funding:** This research was supported by grants from NHLBI (R01HL150877, R61 HL154116), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (HI16C2211), and National Research Foundation of Korea (NRF) funded by the Korean government (MSIT) (No. 2020R1A2C3003784, No.2020M3A94038454).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** We appreciate Andrea Wecker for her editorial assistance.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**Abbreviations**

Official NCBI gene symbols are used in this review for the sake of consistency.

- **AcLDL**: Acetylated low-density lipoprotein
- **ACTA2**: Actin alpha 2, smooth muscle
- **ANGPT2**: Angiopoietin-2
- **APLNR**: Apelin receptor
- **ATAC-seq**: Assay for transposase-accessible chromatin using sequencing
- **B3GAT1**: Beta-1,3-glucuronyltransferase 1
- **BLI**: Bioluminescence imaging
- **BMP4**: Bone morphogenetic protein 4
- **CALD1**: Caldesmon 1
- **CB-ECFC**: Cord-blood endothelial colony-forming cell
- **CD34**: CD34 molecule
- **CD44**: CD44 molecule (Indian blood group)
- **CDH5**: Cadherin 5
- **CMC**: Chemistry, Manufacturing, and Control
- **CB-ECFC**: Cord-blood endothelial colony-forming cell
- **cAMP**: Cyclic adenosine monophosphate
- **CNN1**: Calponin 1
- **COL1A1**: Collagen type I alpha 1 chain
- **COL1A1**: Collagen type I alpha 1 chain
- **ENG**: Endoglin
- **EOMES**: Eomesodermin
- **ERG**: ETS-related gene
- **FACS**: Fluorescence-activated cell sorting
- **FBS**: Fetal bovine serum
- **FGF**: Fibroblast growth factor
- **FGF2**: Fibroblast growth factor 2
- **FOXF1**: Forkhead box F1
- **GBX2**: Gastrulation brain homeobox 2
- **GJA1**: Gap junction protein alpha 1
- **GMP**: Good manufacturing practice
- **GO term**: Gene Ontology term
| Gene Symbol | Description |
|-------------|-------------|
| GSK3β      | Glycogen synthase kinase 3 beta |
| hBM        | Human bone marrow mononuclear cell |
| hESC       | Human embryonic stem cell |
| hiPSC      | Human induced pluripotent stem cell |
| HUVECs     | Human umbilical cord endothelial cells |
| iEnd       | Induced EC via transfection of fibroblasts with POU5F1 and KLF4 |
| ITGA2      | Integrin subunit alpha 2 |
| KDR        | Kinase insert domain receptor |
| KEGG pathway | Database of metabolic pathways from Kyoto Encyclopedia of Genes and Genomes |
| KLF4       | Kruppel-like factor 4 |
| LIN28A     | Lin-28 homolog A |
| LMOD1      | Leiomodin 1 |
| Lrp5 and 6 | Low density lipoprotein receptor-related protein 5 and 6 |
| MAP2K7     | Mitogen-activated protein kinase 7 |
| MCAM       | Melanoma cell adhesion molecule |
| MEOX1      | Mesenchymal homeobox 1 |
| MITCH-PEG  | Mixing-Induced Two-Component Hydrogels combined with PolyEthylene Glycol hybrid hydrogel |
| MIXL1      | Mix paired-like homeobox 1 |
| MRTFA and B| Myocardin related transcription factor A and B |
| MYC        | MYC proto-oncogene, bHLH transcription factor |
| MYH11      | Myosin heavy chain 11 |
| MYH11b     | Myosin, heavy chain 11b, smooth muscle (Danio rerio (zebrafish)) |
| MYLK       | Myosin light chain kinase |
| MYOCD      | Myocardin |
| NANOG      | Nanog homeobox |
| NES        | Nestin |
| NGFR       | Nerve growth factor receptor |
| NKX2-5     | NK2 homeobox 5 |
| NO         | Nitric oxide |
| NOTCH1     | Notch receptor 1 |
| NOS3       | Nitric oxide synthase 3 |
| NRP1       | Neuropilin 1 |
| NT5E       | 5'-Nucleotidase ecto |
| OLIG3      | Oligodendrocyte transcription factor 3 |
| PAX1, 3, and 7 | Paired box 1, 3, and 7 |
| PDGFB      | Platelet-derived growth factor subunit B |
| PDGFRα and β| Platelet-derived growth factor receptor alpha and beta |
| PECAM1     | Platelet and endothelial cell adhesion molecule 1 |
| PI3K       | Phosphatidylinositol-4,5-bisphosphate 3-kinase |
| PITX2      | Paired like homeodomain 2 |
| POU5F1     | POU class 5 homeobox 1 |
| RA         | Retinoic acid |
| ROCK       | Rho-associated protein kinase |
| RT-PCR     | Reverse transcription polymerase chain reaction |
| SHIELD     | Long-term Delivery |
| SMC        | Smooth muscle cell |
| SMTN       | Smoothelin |
| SOX1, 2, 9, and 10 | SRY-box transcription factor 1, 2, 9, and 10 |
| SRF        | Serum response factor |
| SYNPO2     | Synaptodotin 2 |
| TAGLN      | Transgelin |
| TBX6 and T | T-box transcription factor 6 and T |
| TCF15      | Transcription factor 15 |
| TEK        | Tyrosine kinase |
References

1. World Health Organization. The Top 10 Causes of Death. Available online: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (accessed on 12 August 2021).

2. Lopez, A.D.; Murray, C.C. The global burden of disease, 1990–2020. *Nat. Med.* 1998, 4, 1241–1243. [CrossRef] [PubMed]

3. Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y.; et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012, 380, 2095–2128. [CrossRef]

4. Schillinger, M.; Sabeti, S.; Loewe, C.; Dick, P.; Amighi, J.; Mlekusch, W.; Schlager, O.; Cejna, M.; Lammer, J.; Minar, E. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. *N. Engl. J. Med.* 2006, 354, 1879–1888. [CrossRef] [PubMed]

5. Warfarin Antiplatelet Vascular Evaluation Trial, I.; Anand, S.; Yusuf, S.; Xie, C.; Pogue, J.; Eikelboom, J.; Budaj, A.; Sussex, B.; Liu, L.; Guzman, R.; et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. *N. Engl. J. Med.* 2007, 357, 217–227. [CrossRef]

6. Serruys, P.W.; Morice, M.C.; Kappetein, A.P.; Colombo, A.; Holmes, D.R.; Mack, M.J.; Stabile, E.; Feldman, T.E.; van den Brand, M.; Bass, E.J.; et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *N. Engl. J. Med.* 2009, 360, 961–972. [CrossRef] [PubMed]

7. Weintraub, W.S.; Grau-Sepulveda, M.V.; Weiss, J.M.; Kolm, P.; Zhang, Z.; Klein, L.W.; Shaw, R.E.; McKay, C.; et al. Comparative effectiveness of revascularization strategies. *N. Engl. J. Med.* 2012, 366, 1467–1476. [CrossRef]

8. Waldo, S.W.; Secemsky, E.A.; O’Brien, C.; Pomerantsev, E.; McNulty, E.J.; Scirica, B.M.; Yeh, R.W. Surgical ineligibility and mortality among patients with unprotected left main or multivessel coronary artery disease undergoing percutaneous coronary intervention. *Circulation* 2014, 130, 2295–2301. [CrossRef] [PubMed]

9. Isner, J.M.; Asahara, T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. *J. Clin. Invest.* 1999, 103, 1231–1236. [CrossRef] [PubMed]

10. Losordo, D.W.; Dimmeler, S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: Part II: Cell-based therapies. *Circulation* 2004, 1089, 2692–2697. [CrossRef] [PubMed]

11. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. *Nat. Med.* 2000, 6, 389–395. [CrossRef] [PubMed]

12. Jain, R.K. Molecular regulation of vessel maturation. *Nat. Med.* 2003, 9, 685–693. [CrossRef] [PubMed]

13. Simons, M. Angiogenesis: Where do we stand now? *Circulation* 2005, 111, 1556–1566. [CrossRef] [PubMed]

14. Risau, W.; Flamme, I. Vasculogenesis. *Annu. Rev. Cell Dev. Biol.* 1995, 11, 73–91. [CrossRef]

15. Risau, W. Differentiation of endothelium. *FASEB J.* 1995, 9, 926–933. [CrossRef]

16. Folkman, J.; Shing, Y. Angiogenesis. *J. Biol. Chem.* 1992, 267, 10931–10934. [CrossRef]

17. Geudens, I.; Gerhardt, H. Coordinating cell behaviour during blood vessel formation. *Development* 2011, 138, 4569–4583. [CrossRef]

18. Moraes, F.; Paye, J.; Mac Gabhann, F.; Zhuang, Z.W.; Zhang, J.; Lanahan, A.A.; Simons, M. Endothelial cell-dependent regulation of arteriogenesis. *Circ. Res.* 2013, 113, 1076–1086. [CrossRef]

19. Losordo, D.W.; Dimmeler, S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: Angiogenic cytokines. *Circulation* 2004, 109, 2487–2491. [CrossRef]

20. Liu, H.; Kennard, S.; Lilly, B. NOTCH3 expression is induced in mural cells through an autoregulatory loop that requires endothelial-expressed JAGGED1. *Circ. Res.* 2009, 104, 466–475. [CrossRef] [PubMed]

21. Murakami, M.; Simons, M. Regulation of vascular integrity. *J. Mol. Med.* 2009, 87, 571–582. [CrossRef] [PubMed]

22. Frontini, M.J.; Nong, Z.; Gros, R.; Drangova, M.; O’Neill, C.; Rahman, M.N.; Akawi, O.; Yin, H.; Ellis, C.G.; Pickering, J.G. Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells. *Nat. Biotechnol.* 2009, 27, 421–427. [CrossRef]

23. Buschmann, I.; Schaper, W. Arteriogenesis Versus Angiogenesis: Two Mechanisms of Vessel Growth. *News Physiol. Sci.* 1999, 14, 121–125. [CrossRef]

24. Helisch, A.; Schaper, W. Arteriogenesis: The development and growth of collateral arteries. *Microcirculation* 2003, 10, 83–97. [CrossRef] [PubMed]

25. Schaper, W.; Scholz, D. Factors regulating arteriogenesis. *Arterioscler. Thromb. Vasc. Biol.* 2003, 23, 1143–1151. [CrossRef] [PubMed]
26. Jackson, K.A.; Majka, S.M.; Wang, H.; Pocius, J.; Hartley, C.J.; Majesky, M.W.; Entman, M.L.; Michael, L.H.; Hirschi, K.K.; Goodell, M.A. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. *J. Clin. Investig.* 2001, 107, 1395–1402. [CrossRef]

27. Kawamoto, A.; Gwon, H.C.; Iwaguro, H.; Yamaguchi, J.I.; Uchida, S.; Masuda, H.; Silver, M.; Ma, H.; Kearney, M.; Isner, J.M.; et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. *Circulation* 2001, 103, 634–637. [CrossRef]

28. Nagaya, N.; Fujii, T.; Iwase, T.; Ohgushi, H.; Itoh, T.; Uematsu, M.; Yamagishi, M.; Mori, H.; Kangawa, K.; Kitamura, S. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. *Am. J. Physiol. Heart Circ. Physiol.* 2004, 287, H2670–H2676. [CrossRef]

29. Ma, N.; Stamm, C.; Kaminski, A.; Li, W.; Kleine, H.D.; Muller-Hilke, B.; Zhang, L.; Ladilov, Y.; Eggel, D.; Steinhoff, G. Human cord blood cells induce angiogenesis following myocardial infarction in NOD/scid-mice. *Cardiovasc. Res.* 2005, 66, 45–54. [CrossRef]

30. Asahara, T.; Murohara, T.; Sullivan, A.; Silver, M.; van der Zee, R.; Li, T.; Witzenbichler, B.; Schatteman, G.; Isner, J.M. Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 1997, 275, 964–967. [CrossRef] [PubMed]

31. Hirata, K.; Li, T.S.; Nishida, M.; Ito, H.; Matsuoka, M.; Kasaoka, S.; Hamano, K. Autologous bone marrow cell implantation as therapeutic angiogenesis for ischemic hindlimb in diabetic rat model. *Am. J. Physiol. Heart Circ. Physiol.* 2003, 284, H66–H70. [CrossRef] [PubMed]

32. Iwase, T.; Nagaya, N.; Fujii, T.; Itoh, T.; Murakami, S.; Matsumoto, T.; Kangawa, K.; Kitamura, S. Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. *Cardiovasc. Res.* 2005, 66, 543–551. [CrossRef] [PubMed]

33. Strauer, B.E.; Brehm, M.; Zeus, T.; Kosterring, M.; Hernandez, A.; Sorg, R.V.; Kogler, G.; Wernet, P. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. *Circulation* 2002, 106, 1913–1918. [CrossRef] [PubMed]

34. Janssens, S.; Dubois, C.; Bogaert, J.; Theunissen, K.; Deroose, C.; Desmet, W.; Kalantzi, M.; Herbots, L.; Sinnaeve, P.; Dens, J.; et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: Double-blind, randomised controlled trial. *Lancet* 2006, 367, 113–121. [CrossRef]

35. Lunde, K.; Solheim, S.; Aakhus, S.; Arnesen, H.; Abdelnoor, M.; Egeland, T.; Endresen, K.; Ilebekk, A.; Mangschaus, A.; Fjeld, J.G.; et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. *N. Engl. J. Med.* 2006, 355, 1199–1209. [CrossRef]

36. Meyer, G.P.; Wollert, K.C.; Lotz, J.; Pirr, J.; Rager, U.; Lippolt, P.; Hahn, A.; Fichtner, S.; Schaefer, A.; Arseniev, L.; et al. Endothelial progenitor cell transplantation after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. *Eur. Heart J.* 2009, 30, 2978–2984. [CrossRef] [PubMed]

37. Ziegelhoeffer, T.; Fernandez, B.; Kostin, S.; Heil, M.; Voswinckel, R.; Helisch, A.; Schaper, W. Bone marrow-derived cells do not incorporate into the adult growing vasculature. *Circ. Res.* 2004, 94, 230–238. [CrossRef]

38. Cho, H.J.; Lee, N.; Lee, J.Y.; Choi, Y.J.; Li, M.; Wecker, A.; Jeong, J.O.; Curry, C.; Qin, G.; Yoon, Y.S. Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. *J. Exp. Med.* 2007, 204, 3257–3269. [CrossRef] [PubMed]

39. Lee, S.; Yoon, Y.S. Revisiting cardiovascular regeneration with bone marrow-derived angiogenic and vasculogenic cells. *Br. J. Pharmacol.* 2013, 169, 290–303. [CrossRef]

40. Thomson, J.A.; Itskovitz-Eldor, J.; Shapiro, S.S.; Waknitz, M.A.; Swiergiel, J.J.; Marshall, V.S.; Jones, J.M. Embryonic stem cell lines derived from human blastocysts. *Science* 1998, 282, 1145–1147. [CrossRef]

41. Reubinoff, B.E.; Pera, M.; Cao, F.; Xie, X.; Patel, M.; Gambhir, S.S.; Robbins, R.C.; Cooke, J.P.; et al. Differentiation, survival, and function of embryonic stem cell derived endothelial cells for ischemic heart disease. *Circulation* 2007, 116, 146–154. [CrossRef]
49. Li, Z.; Wilson, K.D.; Smith, B.; Kraft, D.L.; Jia, F.; Huang, M.; Xie, X.; Robbins, R.C.; Gambhir, S.S.; Weissman, I.L.; et al. Functional and transcriptional characterization of human embryonic stem cell-derived endothelial cells for treatment of myocardial infarction. *PLoS ONE* **2009**, *4*, e8443. [CrossRef]

50. Cho, S.W.; Moon, S.H.; Lee, S.H.; Kang, S.W.; Kim, J.; Lim, J.M.; Kim, H.S.; Kim, B.S.; Chung, H.M. Improvement of postnatal neovascularization by human embryonic stem cell derived endothelial-like cell transplantation in a mouse model of hindlimb ischemia. *Circulation* **2007**, *116*, 2409–2419. [CrossRef]

51. Huang, N.F.; Niiyama, H.; Peter, C.; De, A.; Natkunam, Y.; Fleisser, F.; Li, Z.; Rollins, M.D.; Wu, J.C.; Gambhir, S.S.; et al. Embryonic stem cell-derived endothelial cells engraft into the ischemic hindlimb and restore perfusion. *Arterioscler. Thromb. Vasc. Biol.* **2010**, *30*, 984–991. [CrossRef]

52. Moon, S.H.; Kim, J.S.; Park, S.J.; Lee, H.J.; Do, J.T.; Chung, H.M. A system for treating ischemic disease using human embryonic stem cell-derived endothelial cells without direct incorporation. *Biomaterials* **2011**, *32*, 6445–6455. [CrossRef] [PubMed]

53. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* **2006**, *126*, 663–676. [CrossRef]

54. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* **2007**, *131*, 861–872. [CrossRef] [PubMed]

55. Ye, Z.; Zhan, H.; Mali, P.; Dowey, S.; Williams, D.M.; Jiang, Y.Y.; Dang, C.V.; Spivak, J.L.; Moliterno, A.R.; Cheng, L. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. *Blood* **2009**, *114*, 5473–5480. [CrossRef]

56. Loh, Y.H.; Agarwal, S.; Park, I.H.; Urbach, A.; Huo, H.; Heffner, G.C.; Kim, K.; Miller, J.D.; Ng, K.; Daley, G.Q. Generation of induced pluripotent stem cells from human blood. *Blood* **2009**, *113*, 5476–5479. [CrossRef]

57. Haase, A.; Olmer, R.; Schwanek, K.; Wunderlich, S.; Merkert, S.; Hess, C.; Zweigerdt, R.; Gruh, I.; Meyer, J.; Wagner, S.; et al. Generation of induced pluripotent stem cells from human cord blood. *Cell Stem Cell* **2009**, *5*, 434–441. [CrossRef]

58. Staerk, J.; Dawlaty, M.M.; Gao, Q.; Maetzel, D.; Hanna, J.; Sommer, C.A.; Mostoslavsky, G.; Jaenisch, R. Reprogramming of human peripheral blood cells to induced pluripotent stem cells. *Cell Stem Cell* **2010**, *7*, 20–24. [CrossRef] [PubMed]

59. Zhou, T.; Benda, C.; Duzinger, S.; Huang, Y.; Li, X.; Li, Y.; Guo, X.; Cao, G.; Chen, S.; Hao, L.; et al. Generation of induced pluripotent stem cells from urine. *J. Am. Soc. Nephrol.* **2011**, *22*, 1221–1228. [CrossRef] [PubMed]

60. Zhou, T.; Benda, C.; Duzinger, S.; Huang, Y.; Ho, J.C.; Yang, J.; Wang, Y.; Zhang, Y.; Zhuang, Q.; Li, Y.; et al. Generation of human induced pluripotent stem cells from urine samples. *Nat. Protoc.* **2012**, *7*, 2080–2089. [CrossRef]

61. Yu, J.; Hu, K.; Smuga-Otto, K.; Tian, S.; Stewart, R.; Slukvin, I.I.; Thomson, J.A. Human induced pluripotent stem cells free of vector and transgene sequences. *Science* **2009**, *324*, 797–801. [CrossRef]

62. Zhong, X.; Li, N.; Liang, S.; Huang, Q.; Coukos, G.; Zhang, L. Identification of microRNAs regulating reprogramming factor LIN28 in embryonic stem cells and cancer cells. *J. Biol. Chem.* **2010**, *285*, 41961–41971. [CrossRef] [PubMed]

63. Jia, F.; Wilson, K.D.; Sun, N.; Gupta, D.M.; Huang, M.; Li, Z.; Panetta, N.J.; Chen, Z.Y.; Robbins, R.C.; Kay, M.A.; et al. A nonviral minicircle vector for deriving human iPS cells. *Nat. Methods* **2010**, *7*, 197–199. [CrossRef]

64. Okita, K.; Nakagawa, M.; Hyenjong, H.; Ichisaka, T.; Yamanaka, S. Generation of mouse induced pluripotent stem cells without viral vectors. *Science* **2008**, *322*, 949–953. [CrossRef]

65. Warren, L.; Manos, P.D.; Ashfeldt, T.; Loh, Y.H.; Li, H.; Lao, F.; Ebina, W.; Mandal, P.K.; Smith, Z.D.; Meissner, A.; et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. *Cell Stem Cell* **2010**, *7*, 618–630. [CrossRef] [PubMed]

66. Mandal, P.K.; Rossi, D.J. Reprogramming human fibroblasts to pluripotency using modified mRNA. *Nat. Protoc.* **2013**, *8*, 568–582. [CrossRef]

67. Han, J.W.; Yoon, Y.S. Induced pluripotent stem cells: Emerging techniques for nuclear reprogramming. *Antioxid. Redox Signal.* **2011**, *15*, 1799–1820. [CrossRef]

68. Yu, J.; Vodyanik, M.A.; Smuga-Otto, K.; Antosiewicz-Bourget, J.; Frane, J.L.; Tian, S.; Nie, J.; Jonsdottir, G.A.; Ruotti, V.; Stewart, R.; et al. Induced pluripotent stem cell lines derived from human somatic cells. *Science* **2007**, *318*, 1917–1920. [CrossRef] [PubMed]

69. Taura, D.; Sone, M.; Homma, K.; Oyamada, N.; Takahashi, K.; Tamura, N.; Yamanaka, S.; Nakao, K. Induction and isolation of vascular cells from human induced pluripotent stem cells—Brief report. *Arterioscler. Thromb. Vasc. Biol.* **2009**, *29*, 1100–1103. [CrossRef]

70. Rufaihah, A.J.; Huang, N.F.; Jame, S.; Lee, J.C.; Nguyen, H.N.; Byers, B.; De, A.; Okogbua, J.; Rollins, M.; Reijo-Pera, R.; et al. Endothelial cells derived from human iPSCs increase capillary density and improve perfusion in a mouse model of peripheral arterial disease. *Arterioscler. Thromb. Vasc. Biol.* **2011**, *31*, e72–e79. [CrossRef] [PubMed]

71. Lin, Y.; Gil, C.H.; Yoder, M.C. Differentiation, Evaluation, and Application of Human Induced Pluripotent Stem Cell-Derived Endothelial Cells. *Arterioscler. Thromb. Vasc. Biol.* **2017**, *37*, 2014–2025. [CrossRef]

72. Xu, M.; He, J.; Zhang, C.; Xu, J.; Wang, Y. Strategies for derivation of endothelial lineages from human stem cells. *Stem Cell Res. Ther.* **2019**, *10*, 200. [CrossRef]

73. Lee, S.J.; Sohn, Y.D.; Andukuri, A.; Kim, S.; Byun, J.; Han, J.W.; Park, I.H.; Jun, H.W.; Yoon, Y.S. Enhanced Therapeutic and Long-Term Dynamic Vasculization Effects of Human Pluripotent Stem Cell-Derived Endothelial Cells Encapsulated in a Nanomatrix Gel. *Circulation* **2017**, *136*, 1939–1954. [CrossRef]
Belair, D.G.; Whisler, J.A.; Valdez, J.; Velazquez, J.; Molenda, J.A.; Vickerman, V.; Lewis, R.; Daigh, C.; Hansen, T.D.; Mann, D.A.; et al. Human vascular tissue models formed from human induced pluripotent stem cell derived endothelial cells. Stem Cell Rev. Rep. 2015, 11, 511–525. [CrossRef]

Lee, S.J.; Kim, K.H.; Yoon, Y.S. Generation of Human Pluripotent Stem Cell-derived Endothelial Cells and Their Therapeutic Utility. Curr. Cardiol. Rep. 2018, 20, 45. [CrossRef][PubMed]

Patsch, C.; Chaulet-Meylan, L.; Thoma, E.C.; Urich, E.; Heckel, T.; O’ Sullivan, J.F.; Grainger, S.J.; Kapp, F.G.; Sun, L.; Christensen, K.; et al. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat. Cell Biol. 2015, 17, 994–1003. [CrossRef][PubMed]

Harding, A.; Cortez-Toledo, E.; Magner, N.L.; Beegle, J.R.; Coleal-Bergum, D.P.; Hao, D.; Wang, A.; Nolta, J.A.; Zhou, P. Highly Efficient Differentiation of Endothelial Cells from Pluripotent Stem Cells Requires the MAPK and the PI3K Pathways. Stem Cells 2017, 35, 909–919. [CrossRef]

Marcelo, K.L.; Goldie, L.C.; Hirschi, K.K. Regulation of endothelial cell differentiation and specification. Circ. Res. 2013, 112, 1272–1287. [CrossRef]

Kennedy, C.C.; Brown, E.E.; Abutaleb, N.O.; Truskey, G.A. Development and Application of Endothelial Cells Derived From Pluripotent Stem Cells in Microphysiological Systems Models. Front. Cardiovasc. Med. 2021, 8, 620516. [CrossRef][PubMed]

Ferguson, J.E., 3rd; Kelley, R.W.; Patterson, C. Mechanisms of endothelial differentiation in embryonic vasculogenesis. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 2246–2254. [CrossRef][PubMed]

Palis, J.; McGrath, K.E.; Kingsley, P.D. Initiation of hematopoiesis and vasculogenesis in murine yolk sac explants. Blood 1995, 86, 156–163. [CrossRef]

Liu, P.; Wakamiya, M.; Shea, M.J.; Albrecht, U.; Behringer, R.R.; Bradley, A. Requirement for Wnt3 in vertebrate axis formation. Nat. Genet. 1999, 22, 361–365. [CrossRef]

Kelly, O.G.; Pinson, K.I.; Skarnes, W.C. The Wnt co-receptors Lrp5 and Lrp6 are essential for gastrulation in mice. Development 2004, 131, 2803–2815. [CrossRef]

Huelsken, J.; Vogel, R.; Brinkmann, V.; Erdmann, B.; Birchmeier, C.; Birchmeier, W. Requirement for beta-catenin in anterior-posterior axis formation in mice. J. Cell Biol. 2000, 148, 567–578. [CrossRef][PubMed]

Lindsley, R.C.; Gill, J.G.; Kyba, M.; Murphy, T.L.; Murphy, K.M. Canonical Wnt signaling is required for development of embryonic stem cell-derived mesoderm. Development 2006, 133, 3787–3796. [CrossRef]

Winnier, G.; Blessing, M.; Labosky, P.A.; Hogan, B.L. Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev. 1995, 9, 2105–2116. [CrossRef][PubMed]

Candia, A.F.; Watabe, T.; Hawley, S.H.; Onichtchouk, D.; Zhang, Y.; Derynck, R.; Niehrs, C.; Cho, K.W. Cellular interpretation of multiple TGF-beta signals: Intracellular antagonism between activin/BVg1 and BMP-2/4 signaling mediated by Smads. Development 1997, 124, 4467–4480. [CrossRef][PubMed]

Ben-Haim, N.; Lu, C.; Guzman-Ayala, M.; Pescatore, L.; Mesnard, D.; Bischofferger, M.; Naef, F.; Robertson, E.J.; Constam, D.B. The nodal precursor acting via activin receptors induces mesoderm by maintaining a source of its convertases and BMP4. Dev. Cell 2006, 11, 313–323. [CrossRef][PubMed]

Rossant, J.; Tam, P.P. Emerging asymmetry and embryonic patterning in early mouse development. Dev. Cell 2004, 7, 155–164. [CrossRef][PubMed]

Warmsflash, A.; Sorre, B.; Etoc, F.; Siggia, E.D.; Brivanlou, A.H. A method to recapitulate early embryonic spatial patterning in human embryonic stem cells. Nat. Methods 2014, 11, 847–854. [CrossRef][PubMed]

Martyn, I.; Kanno, T.Y.; Ruzo, A.; Siggia, E.D.; Brivanlou, A.H. Self-organization of a human organizer by combined Wnt and Nodal signalling. Nature 2018, 558, 132–135. [CrossRef][PubMed]

Kreuser, U.; Buchert, J.; Haase, A.; Richter, W.; Diederichs, S. Initial WNT/beta-Catenin Activation Enhanced Mesoderm Commitment, Extracellular Matrix Expression, Cell Aggregation and Cartilage Tissue Yield From Induced Pluripotent Stem Cells. Front. Cell Dev. Biol. 2020, 8, 581331. [CrossRef][PubMed]

Amaya, E.; Musci, T.J.; Kirschner, M.W. Expression of a dominant negative mutant of the FGF receptor disrupts mesoderm formation in Xenopus embryos. Cell 1991, 66, 257–270. [CrossRef][PubMed]

Amaya, E.; Stein, P.A.; Musci, T.J.; Kirschner, M.W. FGF signalling in the early specification of mesoderm in Xenopus. Development 1993, 118, 477–487. [CrossRef][PubMed]

Griffin, K.; Patient, R.; Holder, N. Analysis of FGF function in normal and tail zebrafish embryos reveals separate mechanisms for formation of the trunk and the tail. Development 1995, 121, 2983–2994. [CrossRef][PubMed]

Fletcher, R.B.; Harland, R.M. The role of FGF signaling in the establishment and maintenance of mesodermal gene expression in Xenopus. Dev. Dyn. 2008, 237, 1243–1254. [CrossRef][PubMed]

Carballada, R.; Yasuo, H.; Lemare, P. Phosphatidylinositol-3 kinase acts in parallel to the ERK MAP kinase in the FGF pathway during Xenopus mesoderm induction. Development 2001, 128, 35–44. [CrossRef][PubMed]

Yamaguchi, T.P.; Harpal, K.; Henkemeyer, M.; Rossant, J. fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation. Genes Dev. 1994, 8, 3032–3044. [CrossRef][PubMed]

Xu, R.H.; Peck, R.M.; Li, D.S.; Feng, X.; Ludwig, T.; Thomson, J.A. Basic FGF and suppression of BMP signaling sustain undifferentiated proliferation of human ES cells. Nat. Methods 2005, 2, 185–190. [CrossRef][PubMed]
100. Yu, P.; Pan, G.; Yu, J.; Thomson, J.A. FGF2 sustains NANOG and switches the outcome of BMP4-induced human embryonic stem cell differentiation. Cell Stem Cell 2011, 8, 326–334. [CrossRef]

101. Sudheer, S.; Bhushan, R.; Fauler, R.; Lehrach, H.; Adjaye, J. FGF inhibition directs BMP4-mediated differentiation of human embryonic stem cells to syncytiotrophoblast. Stem Cells Dev. 2012, 21, 2987–3000. [CrossRef] [PubMed]

102. Singh, A.M.; Reynolds, D.; Cliff, T.; Ohtsuka, S.; Mattheyes, A.L.; Sun, Y.; Menendez, L.; Kulik, M.; Dalton, S. Signaling network cross-talk in human pluripotent cells: A Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem Cell 2012, 10, 312–326. [CrossRef] [PubMed]

103. Sumi, T.; Tsuneyoshi, N.; Nakatsuji, N.; Suehoro, H. Defining early lineage specification of human embryonic stem cells by the orchestrated balance of canonical Wnt/beta-catenin, Activin/Nodal and BMP signaling. Development 2008, 135, 2969–2979. [CrossRef] [PubMed]

104. Orlota, V.V.; Drabsch, Y.; Freund, C.; Petrus-Reuver, S.; van den Hil, F.E.; Muethosing, S.; Dijke, P.T.; Mummery, C.L. Functionality of endothelial cells and pericytes from human pluripotent stem cells demonstrated in cultured vascular plexus and zebrafish xenografts. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 177–186. [CrossRef]

105. Lian, X.; Bao, X.; Al-Ahmad, A.; Liu, J.; Wu, Y.; Dong, W.; Dunn, K.K.; Shusta, E.V.; Palecek, S.P. Efficient differentiation of human pluripotent stem cells to endothelial progenitors via small-molecule activation of WNT signaling. Stem Cell Rep. 2014, 3, 804–816. [CrossRef] [PubMed]

106. Liu, X.; Qi, J.; Xu, X.; Zeisberg, M.; Guan, K.; Zeisberg, E.M. Differentiation of functional endothelial cells from human induced pluripotent stem cells: A novel and efficient method. Differentiation 2016, 92, 225–236. [CrossRef] [PubMed]

107. Wang, K.; Lin, R.Z.; Hong, X.; Ng, A.H.; Lee, C.N.; Neumeyer, J.; Wang, G.; Wang, X.; Ma, M.; Pu, W.T.; et al. Robust differentiation of human pluripotent stem cells into endothelial cells via temporal modulation of ETV2 with modified mRNA. Sci. Adv. 2020, 6, eaba7606. [CrossRef]

108. Chadwick, K.; Wang, L.; Li, L.; Menendez, P.; Murdoch, B.; Rouleau, A.; Bhatia, M. Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic blood cells. Blood 2003, 102, 906–915. [CrossRef]

109. Goldman, O.; Feraud, O.; Boyer-Di Ponio, J.; Driancourt, C.; Clay, D.; Le Bousse-Kerdiles, M.C.; Bennaceur-Griscelli, A.; Uzan, G. A boost of BMP4 accelerates the commitment of human embryonic stem cells to the endothelial lineage. Stem Cells 2009, 27, 1750–1759. [CrossRef]

110. Choi, K.D.; Yu, J.; Smuga-Otto, K.; Salvagiotti, G.; Rehrauer, W.; Vodyanik, M.; Thomson, J.; Slukvin, I. Hematopoietic and endothelial differentiation of human embryonic stem cells: Analysis of functional and differentiation efficiency. Stem Cells 2009, 27, 559–567. [CrossRef] [PubMed]

111. Yang, J.; Li, M.; Kamei, N.; Alev, C.; Kwon, S.M.; Kawamoto, A.; Akimaru, H.; Masuda, H.; Sawa, Y.; Asharaha, T. CD34+ cells represent highly functional endothelial progenitor cells in murine bone marrow. PLoS ONE 2011, 6, e20219. [CrossRef] [PubMed]

112. Prasain, N.; Lee, M.R.; Vemula, S.; Meador, J.L.; Yoshimoto, M.; Ferkowicz, M.J.; Fett, A.; Gupta, M.; Rapp, B.M.; Saadatzadeh, M.R.; et al. Differentiation of human pluripotent stem cells to cells similar to cord-blood endothelial colony-forming cells. Nat. Biotechnol. 2014, 32, 1151–1157. [CrossRef] [PubMed]

113. Li, J.; Huang, N.F.; Zou, J.; Laurent, T.J.; Lee, J.C.; Okogbaa, J.; Cooke, J.P.; Ding, S. Conversion of human fibroblasts to functional endothelial cells by defined factors. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 1366–1375. [CrossRef]

114. Lamalice, L.; Le Boeuf, F.; Huot, J. Endothelial cell migration during angiogenesis. Circ. Res. 2007, 100, 782–794. [CrossRef]

115. Nourse, M.B.; Halpin, D.; Scatenia, M.; Mortensen, D.J.; Tulloch, N.L.; Hauch, K.D.; Torok-Storb, B.; Ratner, B.D.; Pabon, L.; Murray, C.E. VEGF induces differentiation of functional endothelium from human embryonic stem cells: Implications for tissue engineering. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 80–89. [CrossRef] [PubMed]

116. Chang, H.; Huylebroeck, D.; Verschueren, K.; Guo, Q.; Matzuk, M.M.; Zwijnen, A.; Smad5 knockout mice die at mid-gestation due to vasculogenic defects. Development 1999, 126, 1631–1642. [CrossRef] [PubMed]

117. Yang, X.; Li, C.; Xu, X.; Deng, C. The tumor suppressor SMAD4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 3667–3672. [CrossRef]

118. Ribatti, D.; Urbinati, C.; Nico, B.; Rusnati, M.; Roncali, L.; Presta, M. Endogenous basic fibroblast growth factor is implicated in endothelial-mesenchymal transition through microRNA-20a-mediated repression of canonical TGF-beta signaling. J. Cell Sci. 2016, 129, 569–579. [CrossRef] [PubMed]

119. Liu, Z.J.; Shirakawa, T.; Li, Y.; Soma, A.; Oka, M.; Dotto, G.P.; Fairman, R.M.; Velazquez, O.C.; Herlyn, M. Regulation of Notch1 and DI4 by vascular endothelial growth factor in arterial endothelial cells: Implications for modulating arteriogenesis and angiogenesis. Mol. Cell Biol. 2003, 23, 14–25. [CrossRef] [PubMed]

120. Wang, L.; Xiang, M.; Liu, Y.; Sun, N.; Lu, M.; Shi, Y.; Wang, X.; Meng, D.; Chen, S.; Qin, J. Human induced pluripotent stem cells derived endothelial cells mimicking vascular inflammatory response under flow. Biomechanics 2016, 10, 014106. [CrossRef] [PubMed]

121. Ikuno, T.; Masumoto, H.; Yamazaki, K.; Yoshioka, M.; Minakata, K.; Ikeda, T.; Sakata, R.; Yamashita, J.K. Efficient and robust differentiation of endothelial cells from human induced pluripotent stem cells via lineage control with VEGF and cyclic AMP. PLoS ONE 2017, 12, e0173271. [CrossRef]
124. Paik, D.T.; Tian, L.; Lee, J.; Sayed, N.; Chen, I.Y.; Rhee, S.; Rhee, J.W.; Kim, Y.; Wirka, R.C.; Buikema, J.W.; et al. Large-Scale Single-Cell RNA-Seq Reveals Molecular Signatures of Heterogeneous Populations of Human Induced Pluripotent Stem Cell-Derived Endothelial Cells. *Circ. Res.* 2018, 123, 443–450. [CrossRef]

125. Sumanas, S.; Jorniak, T.; Lin, S. Identification of novel vascular endothelial-specific genes by the microarray analysis of the zebrafish cloche mutants. *Blood* 2005, 106, 534–541. [CrossRef] [PubMed]

126. De Val, S.; Black, B.L. Transcriptional control of endothelial cell development. *Dev. Cell* 2009, 16, 180–195. [CrossRef] [PubMed]

127. Suknuntha, K.; Tao, L.; Brok-Volchanskaya, V.; D’Souza, S.S.; Kumar, A.; Slukvin, I. Optimization of Synthetic mRNA for Highly Efficient Translation and its Application in the Generation of Endothelial and Hematopoietic Cells from Human and Primate Pluripotent Stem Cells. *Stem Cell Rev. Rep.* 2018, 14, 525–534. [CrossRef]

128. Elcheva, I.; Brok-Volchanskaya, V.; Kumar, A.; Liu, P.; Lee, J.H.; Tong, L.; Vodyanik, M.; Swanson, S.; Stewart, R.; Kyba, M.; et al. Direct induction of haematopoietic programs in human pluripotent stem cells by transcriptional regulators. *Nat. Commun.* 2014, 5, 4372. [CrossRef] [PubMed]

129. Lindgren, A.G.; Veldman, M.B.; Lin, S. ETV2 expression increases the efficiency of primitive endothelial cell derivation from human embryonic stem cells. *Cell Regen.* 2015, 4, 1. [CrossRef] [PubMed]

130. Sumanas, S.; Jorniak, T.; Lin, S. Identification of novel vascular endothelial-specific genes by the microarray analysis of the zebrafish cloche mutants. *Blood* 2005, 106, 534–541. [CrossRef] [PubMed]

131. De Val, S.; Black, B.L. Transcriptional control of endothelial cell development. *Dev. Cell* 2009, 16, 180–195. [CrossRef] [PubMed]

132. Kume, T. Specification of arterial, venous, and lymphatic endothelial cells during embryonic development. *Histol. Histopathol.* 2010, 25, 637–646. [CrossRef]

133. Swift, M.R.; Weinstein, B.M. Arterial-venous specification during development. *Circ. Res.* 2009, 104, 576–588. [CrossRef] [PubMed]

134. De Val, S.; Black, B.L. Transcriptional control of endothelial cell development. *Dev. Cell* 2009, 16, 180–195. [CrossRef] [PubMed]

135. Arora, S.; Jorniak, T.; Lin, S. Identification of novel vascular endothelial-specific genes by the microarray analysis of the zebrafish cloche mutants. *Blood* 2005, 106, 534–541. [CrossRef] [PubMed]

136. Corada, M.; Morini, M.F.; Dejana, E. Signaling pathways in the specification of arteries and veins. *Arterioscler. Thromb. Vasc. Biol.* 2014, 34, 2372–2377. [CrossRef] [PubMed]

137. Dejana, E.; Hirschi, K.K.; Simons, M. The molecular basis of endothelial cell plasticity. *Nat. Commun.* 2017, 8, 14361. [CrossRef]

138. Simons, M.; Eichmann, A. Molecular controls of arterial morphogenesis. *Circ. Res.* 2015, 116, 1712–1724. [CrossRef] [PubMed]

139. Roca, C.; Adams, R.H. Regulation of vascular morphogenesis by Notch signaling. *Genes Dev.* 2007, 21, 2511–2524. [CrossRef] [PubMed]

140. Corada, M.; Morini, M.F.; Dejana, E. Signaling pathways in the specification of arteries and veins. *Arterioscler. Thromb. Vasc. Biol.* 2014, 34, 2372–2377. [CrossRef] [PubMed]

141. Rosa, S.; Praca, C.; Pitrez, P.R.; Gouveia, P.J.; Aranguren, X.L.; Ricotti, L.; Ferreira, L.S. Functional characterization of human pluripotent stem cell-derived arterial endothelial cells exhibit functional heterogeneity. *Am. J. Transl. Res.* 2013, 5, 21–35.

142. De Val, S.; Black, B.L. Transcriptional control of endothelial cell development. *Dev. Cell* 2009, 16, 180–195. [CrossRef] [PubMed]

143. Arora, S.; Jorniak, T.; Lin, S. Identification of novel vascular endothelial-specific genes by the microarray analysis of the zebrafish cloche mutants. *Blood* 2005, 106, 534–541. [CrossRef] [PubMed]

144. Adams, W.J.; Zhang, Y.; Cloutier, J.; Kuchimanchi, P.; Newton, G.; Sehrawat, S.; Aird, W.C.; Mayadas, T.N.; Luscinskas, F.W.; et al. Human arterial- and venous-like endothelial cells. *Stem Cell Rep.* 2019, 12, 848–861. [CrossRef]

145. Forstermann, U.; Munzel, T. Endothelial nitric oxide synthase in vascular disease: From marvel to menace. *Circulation* 2006, 113, 1708–1714. [CrossRef] [PubMed]

146. Haudenschild, C.C. Morphology of vascular endothelial cells in culture. In *Histology and Histopathology*, 7th ed.; Jaffe, E.A., Ed.; Springer: Boston, MA, USA, 1984; pp. 129–140.

147. Marcu, R.; Choi, Y.J.; Xue, J.; Fortin, C.L.; Wang, Y.; Nagao, R.J.; Xu, J.; MacDonald, J.W.; Bammler, T.K.; Murre, C.E.; et al. Human Organ-Specific Endothelial Cell Heterogeneity. *iScience* 2018, 4, 20–35. [CrossRef]

148. Tousoulis, D.; Kompolli, A.M.; Tentolouris, C.; Papageorgiou, N.; Stefanidis, C. The role of nitric oxide on endothelial function. *Curr. Vasc. Pharmacol.* 2012, 10, 4–18. [CrossRef] [PubMed]

149. White, M.P.; Rufaihah, A.J.; Liu, L.; Ghebremariam, Y.T.; Ivey, K.N.; Cooke, J.P.; Srivastava, D. Limited gene expression variation in human embryonic stem cell and induced stem cell-derived endothelial cells. *Stem Cells* 2013, 31, 92–103. [CrossRef]

150. Koijima, H.; Sakurai, K.; Kikuchi, K.; Kawahara, S.; Kirino, Y.; Nagoshi, H.; Hirata, Y.; Akaike, T.; Maeda, H.; Nagano, T. Development of a fluorescent indicator for the bioimaging of nitric oxide. *Biol. Pharm. Bull.* 1997, 20, 1229–1232. [CrossRef] [PubMed]
Bao, X.; Lian, X.; Dunn, K.K.; Shi, M.; Han, T.; Qian, T.; Bhute, V.J.; Canfield, S.G.; Palecek, S.P. Chemically-defined albumin-free differentiation of human pluripotent stem cells to endothelial progenitor cells. *Stem Cell Res.* 2015, 15, 122–129. [CrossRef]

Bajpai, V.K.; Mistriotis, P.; Loh, Y.H.; Daley, G.Q.; Andreassis, S.T. Functional vascular smooth muscle cells derived from human induced pluripotent stem cells via mesenchymal stem cell intermediates. *Cardiovasc. Res.* 2012, 96, 391–400. [CrossRef]

Kumar, A.; D’Souza, S.S.; Moskvin, O.V.; Toh, H.; Wang, B.; Zhang, J.; Swanson, S.; Guo, L.W.; Thomson, J.A.; Slukvin, I.I. Specification and Diversification of Pericytes and Smooth Muscle Cells from Mesenchymoangioblasts. *Cell Rep.* 2017, 19, 1902–1916. [CrossRef]

Vodyyanik, M.A.; Yu; J.; Zhang, X.; Tian, S.; Stewart, R.; Thomson, J.A.; Slukvin, I.I. A mesoderm-derived precursor for mesenchymal stem and endothelial cells. *Cell Stem Cell* 2010, 7, 718–729. [CrossRef]

Uenishi, G.; Theisen, D.; Lee, J.H.; Kumar, A.; Raymond, M.; Vodyyanik, M.; Swanson, S.; Stewart, R.; Thomson, J.; Slukvin, I. Tenascin C promotes hematopoietic development and T lymphoid commitment from human pluripotent stem cells in chemically defined conditions. *Stem Cell Rep.* 2014, 3, 1073–1084. [CrossRef]

Owens, G.K.; Kumar, M.S.; Wamhoff, B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. *Physiol. Rev.* 2004, 84, 767–801. [CrossRef]

Rasmussen, L.M.; Wolf, Y.G.; Ruoslahti, E. Vascular smooth muscle cells from injured rat aortas display elevated matrix production associated with transforming growth factor-beta activity. *Am. J. Pathol.* 1995, 147, 1041–1048.

Karamariti, E.; Margariti, A.; Winkler, B.; Wang, X.; Hong, X.; Baban, D.; Ragoussis, J.; Huang, Y.; Han, J.D.; Wong, M.M.; et al. Smooth muscle cells differentiated from reprogrammed embryonic fibroblasts through DKK3 signaling are potent for tissue engineering of vascular grafts. *Circ. Res.* 2013, 112, 1433–1443. [CrossRef]

Xiao, Q.; Zeng, L.; Zhang, Z.; Hu, Y.; Xu, Q. Stem cell-derived Sca-1+ progenitors differentiate into smooth muscle cells, which is mediated by collagen IV-integrin alpha1/beta1/alphav and PDGF receptor pathways. *Am. J. Physiol. Cell Physiol.* 2007, 292, C342–C352. [CrossRef]

Lindahl, P.; Johansson, B.R.; Leveen, P.; Betsholtz, C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. *Science* 1997, 277, 242–245. [CrossRef]

Benjamin, L.E.; Hemo, I.; Keshet, E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. *Development* 1998, 125, 1591–1598. [CrossRef]

Hellstrom, M.; Kalen, M.; Lindahl, P.; Abramsson, A.; Betsholtz, C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. *Development* 1999, 126, 3047–3055. [CrossRef]

Owens, G.K.; Geisterfer, A.A.; Yang, Y.W.; Komoriya, A. Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. *J. Cell Biol.* 1988, 107, 771–780. [CrossRef]

Bjorkerud, S. Effects of transforming growth factor-beta 1 on human arterial smooth muscle cells in vitro. *Arterioscler. Thromb.* 1991, 11, 892–902. [CrossRef]

Deaton, R.A.; Su, C.; Valencia, T.G.; Grant, S.R. Transforming growth factor-beta1-induced expression of smooth muscle marker genes involves activation of PKN and p38 MAPK. *J. Biol. Chem.* 2005, 280, 31172–31181. [CrossRef]

Servant, M.J.; Giasson, E.; Meloche, S. Inhibition of growth factor-induced protein synthesis by a selective MEK inhibitor in aortic smooth muscle cells. *J. Biol. Chem.* 1996, 271, 16047–16052. [CrossRef]

Dash, B.C.; Levi, K.; Schwab, J.; Luo, J.; Bartulos, O.; Wu, H.; Qiu, C.; Yi, T.; Ren, Y.; Campbell, S.; et al. Tissue-Engineered Vascular Rings from Human iPSC-Derived Smooth Muscle Cells. *Stem Cell Rep.* 2016, 7, 19–28. [CrossRef]

Wanjare, M.; Kusuma, S.; Gerecht, S. Derivation and maturation of synthetic and contractile vascular smooth muscle cells from human pluripotent stem cells. *Cardiovasc. Res.* 2013, 97, 321–330. [CrossRef]

Wanjare, M.; Kusuma, S.; Gerecht, S. Defining differences among perivascular cells derived from human pluripotent stem cells. *Stem Cell Rep.* 2014, 2, 561–575. [CrossRef]

Frid, M.G.; Shkhotokin, B.V.; Koteliansky, V.E.; Glukhova, M.A. Phenotypic changes of human smooth muscle cells during development: Late expression of heavy caldesmon and calponin. *Dev. Biol.* 1992, 153, 185–193. [CrossRef]

Frid, M.G.; Moiseeva, E.P.; Stenmark, K.R. Multiple phenotypically distinct smooth muscle cell populations exist in the adult and developing bovine pulmonary arterial media in vivo. *Circ. Res.* 1994, 75, 669–681. [CrossRef]

Glukhova, M.A.; Frid, M.G.; Koteliansky, V.E. Phenotypic changes of human aortic smooth muscle cells during development and in adult. *J. Atheroscler. Thromb.* 1994, 1 (Suppl. 1), S47–S49. [CrossRef] [PubMed]

Villaschi, S.; Nicosia, R.F.; Smith, M.R. Isolation of a morphologically and functionally distinct smooth muscle cell type from the intimal aspect of the normal rat aorta. Evidence for smooth muscle cell heterogeneity. *Vitr. Cell. Dev. Biol. Anim.* 1994, 1048, 589–595. [CrossRef]

Chamley-Campbell, J.; Campbell, G.R.; Ross, R. The smooth muscle cell in culture. *Physiol. Rev.* 1979, 59, 1–61. [CrossRef] [PubMed]

Arzensian, S.; Weinhold, B.; Oelgeschlager, M.; Ruther, U.; Nordheim, A. Serum response factor is essential for mesoderm formation during mouse embryogenesis. *EMBO J.* 1998, 17, 6289–6299. [CrossRef]

Li, S.; Wang, D.Z.; Wang, Z.; Richardson, J.A.; Olson, E.N. The serum response factor coactivator myocardin is required for vascular smooth muscle development. *Proc. Natl. Acad. Sci. USA* 2003, 100, 9366–9370. [CrossRef]
251. Sekine, K.; Tsuchi, S.; Yasui, R.; Kobayashi, T.; Ikeda, K.; Hamada, Y.; Kanai, E.; Camp, J.G.; Treutlein, B.; Ueno, Y.; et al. Robust detection of undifferentiated iPSC among differentiated cells. Sci. Rep. 2020, 10, 10293. [CrossRef]

252. Gutierrez-Aranda, I.; Ramos-Mejia, V.; Bueno, C.; Munoz-Lopez, M.; Real, P.J.; Macia, A.; Sanchez, L.; Ligero, G.; Garcia-Perez, J.L.; Menendez, P. Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem Cells 2010, 28, 1568–1570. [CrossRef]

253. Koz, M.; Baj-Krzyworzeka, M.; Sztanek, R.; Mustial-Wysocka, A.; Suda-Szczurek, M.; Majka, M. The Importance of HLA Assessment in “Off-the-Shelf” Allogeneic Mesenchymal Stem Cells Based-Therapies. Int. J. Mol. Sci. 2019, 20, 5680. [CrossRef]

254. Creane, M.; Howard, L.; O’Brien, T.; Coleman, C.M. Biodistribution and retention of locally administered human mesenchymal stromal cells: Quantitative polymerase chain reaction-based detection of human DNA in murine organs. Cytotherapy 2017, 19, 384–394. [CrossRef] [PubMed]

255. Xing, Z.; Zhao, C.; Wu, S.; Zhang, C.; Liu, H.; Fan, Y. Hydrogel-based therapeutic angiogenesis: An alternative treatment strategy for critical limb ischemia. Biomaterials 2021, 274, 120872. [CrossRef]

256. Li, R.K.; Jia, Z.Q.; Weisel, R.D.; Merante, F.; Mickle, D.A. Smooth muscle cell transplantation into myocardial scar tissue improves heart function. J. Mol. Cell. Cardiol. 1999, 31, 513–522. [CrossRef]

257. Fujii, T.; Yau, T.M.; Weisel, R.D.; Ohno, N.; Mickle, D.A.; Shiono, N.; Matsubayashi, K.; Li, R.K. Cell transplantation to prevent heart failure: A comparison of cell types. J. Thorac. Cardiovasc. Surg. 1999, 118, 715–724. [CrossRef]

258. Liu, T.B.; Fedak, P.W.; Weisel, R.D.; Yasuda, T.; Kiani, G.; Mickle, D.A.; Jia, Z.Q.; Li, R.K. Enhanced IGF-1 expression improves smooth muscle cell engraftment after cell transplantation. Am. J. Physiol. Heart Circ. Physiol. 2004, 287, H2840–H2849. [CrossRef] [PubMed]

259. Nakamura, Y.; Yasuda, T.; Weisel, R.D.; Li, R.K. Enhanced cell transplantation: Preventing apoptosis increases cell survival and ventricular function. Am. J. Physiol. Heart Circ. Physiol. 2006, 291, H939–H947. [CrossRef] [PubMed]

260. Yoo, K.J.; Li, R.K.; Weisel, R.D.; Mickle, D.A.; Li, G.; Yau, T.M. Autologous smooth muscle cell transplantation improved heart function in dilated cardiomyopathy. Ann. Thorac. Surg. 2000, 70, 859–865. [CrossRef]

261. Yoo, K.J.; Li, R.K.; Weisel, R.D.; Mickle, D.A.; Tomita, S.; Ohno, N.; Fujii, T. Smooth muscle cells transplantation is better than heart cells transplantation for improvement of heart function in dilated cardiomyopathy. Yonsei Med. J. 2002, 43, 296–303. [CrossRef]